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General Introduction 
 
Obesity and insulin resistance 
Obesity prevalence 
The prevalence of obesity has risen to epidemic proportions over the last decades and affects 
people of all ages and socioeconomic groups (1). In 2014, more than 39% of the world adult 
population was overweight (BMI > 25 kg/m2) and about 13% was obese (BMI > 30 kg/m2) 
(2). In 2015, in the Netherlands, over 50% of the individuals over 20 years of age were 
overweight or obese (3).  
The increasing prevalence of obesity is a major health concern. In 2010, overweight 
and/or obesity was estimated to cause 3.4 million deaths worldwide (4). Additionally, obesity 
increases the risk for developing chronic diseases such as type 2 diabetes mellitus (5), 
cardiovascular diseases (6), mental disorders (7) and several cancer types (8). In the upcoming 
years, the expectation is that obesity-related complications will continue to increase and will 
have large public health and socioeconomic consequences.  
Obesity and cardiometabolic health 
A disrupted energy homeostasis, due to a dysbalance between energy intake and energy 
expenditure, is often accompanied by the development of obesity and its related metabolic 
complications. A positive energy balance, which is a long-term surplus of energy intake from 
carbohydrates, lipids and/or proteins over energy expenditure, leads to energy storage as fat in 
the body and to weight gain (9). An inactive lifestyle as well as calorie-dense food 
consumption are main causes for body weight changes, next to genetic predisposition and 
other environmental and biological factors (10). Impaired energy homeostasis and obesity are 
strongly associated with insulin resistance, development of type 2 diabetes and 
cardiometabolic complications (11).  
Obesity is linked to the development of insulin resistance, which is defined as an impaired 
sensitivity to insulin of its main metabolic target organs e.g. adipose tissue, skeletal muscle, 
liver and pancreas. Insulin resistance is a major contributor to hyperglycemia and 
hyperlipidemia, which are all risk factors towards the development of type 2 diabetes and 
cardiovascular diseases. Notably, the ‘World Health Organization (WHO) Global report on 
diabetes 2016’ reports a doubled prevalence of diabetes since 1980, rising from 4.7% to 8.5% 
in the worldwide adult population. Moreover, this report estimates the total burden of deaths 
from high blood glucose near 3.7 million cases (12), including 2.2 million deaths caused by 
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higher-than-optimal blood glucose concentrations and related cardiovascular disease 
complications (12). In addition, the WHO estimated that 17.7 million people died from 
cardiovascular diseases in 2015, representing 31% of all global deaths (13). Strikingly, insulin 
resistance increases the risk for cardiovascular diseases even in the absence of hyperglycemia 
(14,15). Thus, understanding the etiology of insulin resistance is a key step in the prevention 
of cardiometabolic diseases.  
Insulin resistance and tissue-specificity 
In humans, intermediate states of impaired glucose metabolism (prediabetes) can be identified 
by measuring plasma glucose and insulin concentrations in the fasting state and after an oral 
glucose tolerance test (OGTT). Insulin resistance together with increased β-cell failure results 
in an increased blood glucose concentrations in the non-diabetic range. These prediabetes 
states are classified as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) 
(16). Individuals with IFG, defined by fasting glucose > 5.6 mmol/L, mainly show hepatic 
insulin resistance and a normal or slightly lower whole-body insulin sensitivity. In contrast, 
individuals with IGT, defined by a 2 h glucose concentration > 7.8 mmol/L, have a normal 
to slightly reduced hepatic insulin resistance and show moderate to severe reduced peripheral 
(skeletal muscle) insulin sensitivity. However, the pathophysiological mechanisms do overlap 
substantially between IFG and IGT as both states are characterized by hyperglycemia. In 
addition, individuals who have combined IFG and IGT show both hepatic and peripheral 
(skeletal muscle) insulin resistance (17).  
These prediabetes states represent distinct pathophysiological pathways towards 
cardiometabolic diseases. Up to now, there is evidence that interventions that increase insulin 
sensitivity are organ specific, at least for a part of their effects. For instance, physical activity 
was shown to mainly affect muscle insulin sensitivity (18), while metformin treatment might 
improve hepatic insulin resistance (19). In addition, a diet low in fat and high in complex 
carbohydrates may be beneficial for prediabetic individuals with hepatic insulin resistance, 
while the Mediterranean diet may improve muscle insulin sensitivity (20).  
Rodent studies may provide important links to a better understanding of human substrate 
metabolism in relation to insulin resistance. In mice, genetic manipulation of the insulin 
receptor signaling pathways in different organs had major effects on the mice phenotypes and 
metabolic functioning of these organs (21). For instance, mice with muscle–specific insulin 
receptor knockout (MIRKO) had profound insulin resistance in muscle, but glucose tolerance 
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was normal due to insulin–independent glucose uptake in muscle (22). This comes along with 
increased glucose uptake in adipose tissue (22). In mice with liver-specific insulin receptor 
deletion (LIRKO), insulin suppression of hepatic glucose output was completely abolished, 
and hyperlipidemia and progressive liver dysfunction was observed (23). Notably, the 
MIRKO mouse demonstrated a development of adaptive mechanisms in adipose tissue to 
compensate for muscle insulin resistance to maintain glucose homeostasis while the LIRKO 
mouse was unable to respond to hyperinsulinemia (21). So far, these rodent studies have 
helped us revealing distint metabolic profiles when insulin receptor signaling pathways are 
affected in a tissue-specific manner. However, human studies focusing on tissue-specific 
insulin resistance phenotypes are limited so far.   
Interorgan cross-talk in obesity and insulin resistance 
As illustrated above, insulin resistance can develop simultaneously in multiple organs and the 
insulin resistance severity may vary between different organs. Insulin tightly regulates the 
distribution and utilization of the energy-rich carbohydrates and fatty acids. Therefore the 
metabolic insulin sensitive organs such as adipose tissue, liver and skeletal muscle play an 
important role in human energy metabolism. Dysfunction of these organs cause or contribute 
to the development of (tissue-specific) insulin resistance and cardiometabolic diseases. 
Figure 1 shows a schematic overview of organ crosstalk in obese insulin resistant conditions.  
Adipose tissue plays a central role in energy metabolism and is closely related to the 
adverse health effects associated with obesity. The two major functions of the adipose tissue 
related to lipid metabolism are: i) lipid storage by the uptake of meal-derived fatty acids from 
the circulation and store them as triacylglycerol (TAG) in the postprandial phase and ii) to 
supply non-adipose tissue with energy in the form of non-esterified fatty acids (NEFAs) in 
conditions of increased energy demand (e.g. fasting and exercise) (9). Under conditions of 
chronic positive energy balance, the adipocytes become enlarged and the adipose tissue lipid 
buffering capacity is often exceeded. This results in lipid overflow into the circulation and 
subsequently to non-adipose tissues such as liver, skeletal muscle and pancreas (24). If lipid 
supply exceeds the fat oxidative capacity in these non-adipose tissues, ectopic fat accumulation 
may occur. This ectopic fat accumulation is associated with the development of insulin 
resistance.  
In the liver, an increased lipid supply from the adipose tissue may stimulate the 
endogenous formation of TAG under obese insulin resistant conditions. The lipid overflow 
 12  | 
 
Chapter 1 
 
leads to elevated secretion of very low-density lipoprotein (VLDL)-TAG into the circulation 
(25). Together with a higher hepatic glucose production and reduced insulin clearance, this 
results in increased systemic glucose and insulin concentrations. Subsequently, these processes 
might affect the lipid overflow to other tissues (26). 
The skeletal muscle is recognized as a key organ in peripheral insulin sensitivity as it 
accounts for 70-80% of the total glucose disposal under postprandial conditions (27). Often 
skeletal muscle insulin resistance refers to an impaired insulin regulation of glucose 
homeostasis. Notably, lipid metabolism is important as well. An increased lipid supply from 
adipose tissue and liver results in an increased uptake of systemic endogenous and dietary 
lipids into the skeletal muscle. Furthermore, a reduced capacity to oxidize fatty acids is often 
observed in obese insulin resistant conditions, which might be due to mitochondrial 
dysfunction (28). These factors together may contribute to the increased accumulation of 
intramuscular lipids (e.g. TAG, diacylglycerol (DAG)) and lipid intermediates (e.g. ceramides 
and acylcarnitines), leading to lipotoxicity and cellular dysfunction (29). Subsequently, these 
processes might disrupt the insulin signaling and insulin-mediated glucose uptake, resulting 
in lipid-induced insulin resistance (30). 
In the pancreas, ectopic fat deposition might result in lipotoxicity and decreased glucose-
stimulated insulin secretion by the beta-cell, thereby accelerating hyperglycemia and the 
development of insulin resistance in other tissues. This process may require a long time as this 
is illustrated by the observation that the obese insulin resistant state is often associated with 
higher plasma insulin concentrations (i.e. compensatory hyperinsulinemia) rather than 
decreased insulin levels (24). 
Finally, the gastrointestinal tract plays a major part in organ crosstalk and lipid 
metabolism as well. The primary task of the gastrointestinal tract is to digest and absorb 
marconutrients, including lipids. For instance, dietary lipids are packaged into lipoprotein 
particles called chylomicrons, which will be transported via the lymphe nodes towards 
peripheral tisues and the liver. Additionally, the gut is an endocrine organ regulating the 
secretion of satiety hormones and incretins, thereby affecting energy and substrate metabolism 
of the host (31). Importantly in the last decade, the residents of the intestine, the gut 
microbiota, have been recognized as an active metabolic organ. They produce short-chain 
fatty acids, bile acids and inflammatory factors with significant impact on host 
energy/substrate metabolism and insulin sensitivity (32). Up to now, there is accumulating 
evidence that obesity-associated alterations in the gut microbiota can also affect host lipid and  
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Figure 1. Schematic overview of inter-organ crosstalk in obesity-induced insulin resistance 
During long-term positive energy balance (i.e. when energy intake exceeds energy expenditure), 
systemic lipid overload contributes to ectopic (non-adipose) lipid storage. Loss of the adipose 
tissue buffer capacity may increase circulating NEFA and TAG. Fatty acids are taken up by 
peripheral tissues like skeletal muscle, liver and pancreas. An impaired lipid oxidation in these 
tissues may direct these lipids towards storage, possibly leading to the development of insulin 
resistance. LPL, located at the luminal side of the capillary endothelium, plays a central role in 
the clearance of TAG-rich plasma lipoprotein particles in skeletal muscle and adipose tissue. In 
addition, inflammatory cytokines may be secreted from adipose tissue and they may decrease 
local and whole-body insulin sensitivity. LPL: lipoprotein lipase, NEFA: non-esterified fatty 
acid, CM-TAG: chylomicron triacylglycerol ( ), VLDL-TAG: very-low density lipoprotein 
triacylglycerol ( ), ectopic lipid storage ( ), inflammatory cytokines ( ).  
 
glucose metabolism in adipose tissue, liver and skeletal muscle. However most mechanistic 
evidence is based on animal studies so far (32,33).  
To better understand the complex inter-organ crosstalk in insulin resistance, the next 
paragraphs will discuss in more detail the role of adipose tissue (dys)function as well as the 
role of liver and skeletal muscle in lipid metabolism and insulin resistance.  
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Adipose tissue function and dysfunction 
The development of obesity is accompanied by a substantial increase in adipose tissue mass. 
However, increased adipose tissue mass per se might not be the most important contributor to 
the development of obesity-related metabolic disorders. Adipose tissue function and 
distribution of body fat may also play a prominent role in cardiometabolic health (34). The 
adipose tissue organ is composed of different discrete anatomical depots, all with different size 
and metabolic function (35,36). Adipose tissue accumulation in the upper body (abdominal 
region) is associated with increased cardiometabolic and mortality risk, while lower body 
(gluteofemoral region) fat accumulation is considered to be protective against obesity-related 
disorders (35). Moreover, with respect to the upper-body adipose tissue depots, enlarged 
visceral adipose tissue confers increased risk for cardiometabolic risk factors compared to 
subcutaneous adipose tissue. This could possibly be due to functional differences such as a 
pro-inflammatory phenotype (37).  
Traditionally, the only function that was ascribed to adipose tissue was that of insulator 
and energy storing tissue. However, nowadays it is commonly accepted that adipose tissue is 
a dynamic endocrine organ. It is involved in the regulation of various homeostatic processes 
including lipid storage and mobilization which is also called lipid buffering capacity. The 
adipose tissue continuously switches from being a net storage organ in times of a positive 
energy balance to a net release organ in times of a negative energy balance. In addition, adipose 
tissue is involved in regulation of appetite and satiety, and secretion of cytokines and 
adipokines related to the development of local and systemic low-grade inflammation (9,38-
40).  
In the next paragraphs, I will discuss the relationship between adipose tissue lipid 
buffering capacity and insulin resistance in more detail. Additionally, I will highlight the role 
of adipose tissue differentiation capacity and adipose tissue inflammation in obesity-induced 
insulin resistance.  
Adipose tissue lipid uptake and storage 
In times of a positive energy balance, i.e. the fed state, the adipose tissue buffers and stores 
dietary fatty acids in the form of TAGs (41). Lipoprotein lipase (LPL), located at the luminal 
side of the capillary endothelium, plays a central role in the clearance of TAG-rich plasma 
lipoproteins particles (42). It is the rate-limiting enzyme in extracellular lipolysis as it catalyzes 
the hydrolysis of endogenous VLDL-TAG and exogenous chylomicron-TAG into glycerol 
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and NEFAs (43). The activity of LPL is under tight nutritional and hormonal control in a 
tissue-specific manner. In humans, adipose LPL activity is markedly elevated in the fasted 
state compared with the fed state (44). While adipose tissue LPL activity oscillates, LPL 
mRNA and protein mass differ only slightly (42). This suggests that the activity of LPL is 
primarily regulated at the post-translational level. Indeed, in adipose tissue, the postprandial 
rise in insulin is a major activator of LPL activity (43,45).  
Recently, angiopoietin-like protein 4 (ANGPTL4) has emerged as an important 
inhibitor of LPL activity in the fasted state (46). But the role of ANGPTL4 in human adipose 
tissue LPL activity is not well understood and current data are mainly derived from animal 
studies. In rodent adipose tissue studies, increased ANGPTL4 concentrations inhibit adipose 
tissue LPL activity via transient binding to LPL and conversion to inactive monomers under 
fasting conditions (47). Moreover, it has been shown that ANGPTL4 promotes intracellular 
degradation of LPL in murine adipocytes in in vitro studies (48). It has also been reported in 
rodent studies that increased ANGPTL4 expression leads to a reduced plasma TAG clearance 
by adipose tissue (49) and this inhibiting effect was blunted in ANGPTL4 knockout mice 
(49). It is known that ANGPTL4 is expressed in human adipocytes (50) and it has been 
shown that during long-term fasting (50) and following acute physical activity (50-52) adipose 
tissue expression and plasma ANGPTL4 concentrations are increased in humans. Moreover, 
insulin has been shown to reduce circulating ANGPTL4, as revealed by hyperinsulinemic-
euglycemic clamp studies in humans (53-55). Nevertheless, it remains to be elucidated 
whether systemic and/or adipose tissue ANGPTL4 levels are also involved in regulating 
adipose tissue LPL activity in humans and whether this is impaired under insulin resistant 
conditions. Besides insulin and ANGPTL4, LPL activity is also regulated by apolipoproteins 
(APO-C1, -2, -3, -5, APO-E), Gastric inhibitory polypeptide (GIP), 
Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 
(GPIHBP1) and other ANGPTLs (-3 and -8), which are reviewed in detail elsewhere 
(42,56). 
LPL activity is not wel understood in humans under obese insulin resistant conditions. 
Basal LPL activity has been reported to be delayed but preserved in obese individuals when 
compared to lean healthy individuals (57). During hyperinsulinemia, it has been shown that 
fatty acid spillover from LPL-mediated TAG hydrolysis across adipose tissue was less 
suppressed in obese individuals (57,58). It was recently demonstrated that men with type 2 
diabetes have a similar ability to store VLDL-TAG in adipose tissue compared to 
non-diabetic men, despite greater circulating postprandial VLDL-TAG concentrations (59). 
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Moreover, a delayed insulin-mediated stimulation of adipose tissue LPL activity was found 
in obesity, insulin resistance and type 2 diabetes (60-64). This resulted in an impaired 
clearance of chylomicron-derived TAG. In obese individuals, a decreased clearance of 
VLDL-TAG by adipose tissue was observed after an overnight fast, whilst in the postprandial 
state chylomicron-TAG clearance was reduced (65). Subsequently, VLDL-TAG seemed to 
compete with chylomicrons for LPL-mediated clearance (60,65). In line, the latter study 
demonstrated that the relative quantity of meal lipids stored in adipose tissue after the intake 
of subsequent meals was significantly reduced in abdominally obese versus lean individuals 
(65). Together, these data suggest a less efficient removal of dietary lipids by adipose tissue 
under obese insulin resistant conditions. The impaired removal of dietary lipids in 
combination with increased liver VLDL production (26,66) may contribute to increased lipid 
spillover and ectopic fat deposition. To summarize, in obese insulin resistant conditions, 
elevated TAG concentrations are observed. Both an increased liver VLDL production (26,66) 
as well a reduced clearance of circulating VLDL-TAG and chylomicron-TAG by adipose 
tissue have been shown to play a significant role in this phenomenon. 
In addition to an impaired LPL action in obese and insulin-resistant conditions, 
disturbances in the uptake of the liberated NEFAs may contribute to an impaired total lipid 
uptake by adipose tissue. A significant proportion of the fatty acids that are hydrolyzed from 
TAG by intravascular LPL lipolysis are not taken up by the adipose tissue and they will ‘spill 
over’ into the plasma NEFA pool (67). Under normal physiological conditions, LPL-derived 
NEFAs are taken up by passive diffusion or active fatty acid transporters, like fatty acid 
translocase (CD36), plasma membrane bound fatty acid binding protein (FABPpm) and a 
family of fatty acid transport proteins (FATP1-6) (68). The process of fatty acids trapping 
into the adipocytes is dependent on the concentration gradient across the adipocyte membrane 
and plasma. The concentration gradient is regulated by enzymes involved in fatty acid re-
esterification and intracellular lipolysis (41,69). In the adipocytes, the NEFAs will be mostly 
directed towards re-esterification and storage of TAG, thereby lowering the NEFA 
concentration intracellularly.  
Adipose tissue lipolysis 
In times of a negative energy balance, e.g. during fasting or increased physical activity, the 
adipose tissue releases fatty acids in the form of NEFAs for oxidation in other organs. This 
process is called intracellular lipolysis (70). It involves the hydrolysis of stored neutral TAGs 
into glycerol and NEFAs via the action of three consecutive lipases: adipose tissue TAG lipase 
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(ATGL), hormone-sensitive lipase (HSL) and monoacylglyceride lipase (MGL) (71,72). The 
catecholamines, adrenalin and noradrenalin, and the natriuretic peptides, atrial natriuretic 
peptide (ANP) and the brain natriuretic peptide (BNP), act as pro-lipolytic hormones, 
whereas insulin is the most potent anti-lipolytic hormone in human adipose tissue (70).  
In obesity, whole-body lipolysis under fasting conditions (also called basal lipolysis) may 
be increased because of the increased total adipose tissue mass. Indeed, an increased total 
NEFA flux is often observed during fasting in obese insulin resistant conditions. In contrast, 
the rate of NEFA release per kg fat mass is considerably decreased in obesity (73). In line, 
this reduced lipolysis per unit fat mass during fasting and catecholamine stimulation has been 
shown to be associated with lower adipose tissue ATGL and HSL expression and activity in 
obese insulin resistant individuals (74,75). Furthermore, insulin-mediated suppression of fatty 
acid release has been shown to be blunted in obesity, impaired glucose tolerant and type 2 
diabetes individuals (62,76). Nevertheless, the differences in circulating NEFA 
concentrations between obese and lean participants are generally modest and appear not to be 
proportionally increased to the size of adipose tissue mass (77). In summary, obesity and 
insulin resistance are characterized by an increased basal and a blunted catecholamine and 
natriuretic peptide-stimulated lipolysis in subcutaneous adipocytes. 
Adipose tissue differentiation capacity  
During periods of a chronic positive energy balance, adipocytes become overloaded with TAG 
and the adipose tissue will expand to accomodate extra TAG storage. This process is firstly 
determined by an increase in adipocyte size (hypertrophy) and subsequently by an increased 
adipocyte number (hyperplasia) through a process called adipogenesis (78). In general, the 
total adipocyte number remains stable during adulthood although cells are renewed during 
life. It has been estimated that there is a yearly ~10% adipocyte turnover (79). During the 
~10 year lifespan of human adipocytes, the TAG content is renewed six times on average (80).  
Hypertrophic adipocytes have been more strongly associated with insulin resistance and 
its metabolic complications than hyperplastic adipose tissue (81-83). Moreover, adipocyte 
hypertrophy has been shown to be a key phenotypic characteristic of non-obese  and obese 
type 2 diabetes patients (84), while adipocyte number was lower compared to BMI-matched 
obese persons without metabolic complications (85-87). Finally, a reduced lipid turnover, due 
to mitochondrial dysfunction, in adipocytes was also associated with obesity (88) and 
hypertrophic dysfunctional adipose tissue (89). Together these data a diminished adipocyte 
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differentiation capacity, which might result in a reduced TAG storing capacity in obese 
insulin resistant individuals. Subsequently, this may contribute to a limited lipid buffering 
capacity. 
Adipose tissue inflammation  
Adipose tissue contains, besides adipocytes, a wide variety of stromal vascular cells, including 
endothelial cells, fibroblasts, preadipocytes and immune cells. The latter have been 
increasingly implicated in the development of insulin resistance (90). Next to being a lipid 
storage organ, adipose tissue is also an secretory organ (40) that actively secretes adipokines, 
including cytokines, chemokines and hormones. These factors can act locally (autocrine 
and/or paracrine) or systemically as they can be secreted into the circulation (figure 1).  
Obese adipose tissue is characterized by secretion of pro-inflammatory cytokines (40), 
but the trigger for adipose tissue low-grade inflammation is poorly understood. Low-grade 
inflammation could originate from a rapid expansion of adipose tissue. This could provide 
intrinsic signals to stimulate an inflammatory response, thereby accommodating tissue 
remodeling (91). These intrinsic signals may include adipocyte death, hypoxia and 
mechanotransduction stress arising from interactions between the cell and the extracellular 
matrix. Alternatively, gut-derived substances such as dietary components or metabolites might 
stimulate an inflammatory response in adipose tissue (92).  
In rodents, an expanded adipose tissue mass is associated with a switch towards a more 
pro-inflammatory phenotype (93). This is accompanied by an increased production of pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) 
and monocyte chemoattractant protein-1 (MCP-1) (39). For instance, mice studies show that 
increased MCP-1 expression attracts macrophages to the adipose tissue, which might polarize 
from anti-inflammatory M2 to pro-inflammatory cytokine producing M1 macrophages 
(94,95). This in turn might create an environment for attraction of other immune cells (96) 
and might accelerate local inflammation (93). However, the role of pro-inflammatory 
macrophages in human adipose tissue is still under intense debate (97).  
Local adipose tissue inflammation interacts also with adipose tissue lipid metabolism. 
Through release of inflammatory factors, immune cells can affect adipose tissue lipid buffering 
capacity and lipolysis (98). For instance, in vitro studies show that IL-6 and TNF-α stimulate 
adipocyte lipolysis (99-101), and might thereby contribute to systemic fatty acid release. 
Moreover, these cytokines can inhibit adipocyte differentiation (102,103), further limiting 
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adipose tissue buffering capacity. This deteriorates adipose tissue function and accelerates 
local and whole-body insulin resistance.  
In addition, adipose tissue inflammation might result in systemic low-grade 
inflammation and may exert detrimental effects on insulin signaling in peripheral tissues, 
including skeletal muscle and liver. For example, in vitro evidence shows that adipose tissue 
derived TNF-α impairs GLUT-4 translocation and glucose uptake in human myotubes, 
although findings are inconsistent (104,105). Moreover, it has been demonstrated that the 
adipokine adiponectin increases skeletal muscle and liver fat oxidation in vitro (106,107). 
Therefore, decreased adiponectin concentrations, as observed in obese conditions, may impact 
fat oxidation, and as such, affect lipid accumulation and insulin sensitivity in both skeletal 
muscle and liver.  
Hepatic lipid metabolism  
The liver plays an important role in whole-body lipid homeostasis and a pathophysiological 
link between hepatic lipid metabolism and insulin resistance has been known for decades (26). 
Hepatic insulin resistance is related to accumulation of lipid metabolites in the liver, which 
may be caused by multiple factors (108). This phenomenon can be explained by an increased 
NEFA supply from the expanded visceral adipose tissue (the ‘portal hypothesis’) or an 
increased intake of dietary fat. In addition, hepatic lipid accumulation may be explained by a 
reduction in postprandial lipid clearance, an increased uptake of lipoprotein remnants and an 
increased spillover of NEFA from subcutaneous adipose tissue in the circulation (109,110). 
Furthermore, hepatic mitochondrial dysfunction and an increased de novo lipogenesis are 
associated with elevated hepatic lipid accumulation as well (111,112). These processes are 
reviewed in detail elsewhere (24,26). 
As mentioned before, insulin resistance is also linked with an increased secretion of 
hepatic VLDL-TAG. One role of VLDL is to transport excess energy out of the liver, 
predominantly in the form of TAG, which in turn elevates plasma TAG levels. VLDL 
assembly and secretion is a substrate-dependent process that is highly regulated by the 
availability of fatty acids (25). The fatty acids that are used for VLDL synthesis originate from 
several endogenous sources. They are mainly coming from the circulating NEFA pool, 
lipoprotein remnants that are cleared by the liver, intracellular lipids and de novo lipogenesis 
(113). The total flux of lipids to the liver is an important determinant of hepatic VLDL 
production and secretion, which can be suppressed by insulin (114,115). Hepatic insulin 
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resistance may increase circulating VLDL-TAG concentrations due to diminished insulin-
mediated suppression of VLDL production and secretion (26). In addition, as VLDL- and 
chylomicron-TAG compete for the same clearance by LPL in peripheral tissues (116), 
increased VLDL-TAG in the fasting state may result in delayed clearance of TAG-rich 
lipoprotein particles in the postprandial state due to prolonged elevated VLDL-TAG 
concentrations. 
Skeletal muscle function and dysfunction 
As skeletal muscle is responsible for 70-80% of insulin-stimulated whole-body glucose 
disposal, it plays an important role in the pathogenesis of whole-body insulin resistance (27). 
Disturbances in skeletal muscle lipid metabolism have been suggested to contribute to the 
development of muscle insulin resistance and type 2 diabetes (30).  
An increased lipid supply from adipose tissue and liver may result in an increased muscle 
uptake of systemic lipids, but this depends on the source and type of fatty acids. An increased 
lipid supply together with a reduced capacity to adapt fat oxidation accordingly might 
contribute to the accumulation of detrimental bioactive lipid intermediates, such as DAG and 
ceramides (29). This in turn may induce lipotoxicity. In recent years, it has become clear that 
there is a complex interplay between lipid supply, muscle lipid turnover and subcellular 
localization and composition of bioactive lipid metabolites. All these factors are involved in 
the development of a reduced insulin-mediated glucose uptake. They may interfere with the 
glucose transporter 4 (GLUT-4) translocation to the skeletal muscle membrane (117).  
In the next paragraphs, skeletal muscle lipid metabolism will be described in more detail. 
Lipid uptake, muscle LPL activity, lipid synthesis, lipolysis, lipid oxidation and lipotoxicity 
will be reviewed. In addition, it will be discussed how a disturbed lipid metabolism may 
contribute to the development of insulin resistance. 
Skeletal muscle lipid uptake 
Under fasting conditions, skeletal muscle takes up fatty acids derived from the plasma NEFA 
pool as well as those liberated after LPL-mediated lipolysis of VLDL-TAG in the capillary 
bed of skeletal muscle. However, the quantitive contribution of the latter process compared 
to total NEFA uptake in fasting conditions is not clear. A slightly but significantly higher 
uptake of plasma-derived NEFA during fasting has been shown in skeletal muscle of obese 
versus lean (118) and insulin-resistant versus control individuals (63). This increased uptake 
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was observerd despite comparable plasma NEFA concentrations. In contrast, two other 
human in vivo studies showed no difference in skeletal muscle fatty acid uptake (119,120). 
The first study compared an insulin resistant group with a control group, while the second 
compared impaired glucose tolerant individuals with normal glucose tolerant individuals. 
Despite the somewhat contradicting results, these data may point towards more pronounced 
disturbances in TAG metabolism rather than NEFA under obese insulin resistant conditions.   
In the postprandial state, both VLDL-TAG and chylomicron-TAG are present in the 
circulation and these particles compete for LPL-mediated hydrolysis. It has been shown that 
chylomicron-TAG is the preferred substrate for LPL, but it competes with VLDL-TAG for 
extracellular lipolysis (116). VLDL-TAG makes a large contribution to circulating TAG, 
even in the postprandial phase (121). Compared to adipose tissue, it has been suggested that 
uptake of TAG-derived fatty acids after LPL hydrolysis is more efficient in skeletal muscle 
(122). Moreover, substantial fatty acid spillover also occurs in skeletal muscle, although it has 
been suggested that the extent of fatty acid spillover is less in skeletal muscle than in adipose 
tissue (123). These fatty acids merge with the plasma NEFA pool to compete for cellular 
uptake (124).  
The contribution of TAG-derived fatty acids to skeletal muscle lipid uptake may be at 
least equally important as plasma NEFA (122,124). Elevated plasma TAG concentrations 
have been associated with whole-body insulin resistance. As discussed above, this might be 
due to increased liver VLDL production (26,66) and/or impaired clearance of circulating 
TAG by adipose tissue in the postprandial state (60-64). Previously, our group has 
demonstrated higher postprandial plasma TAG concentrations and an increased net TAG 
extraction across forearm muscle in individuals with IFG compared to IGT (125). 
Furthermore, despite a similar TAG supply, we showed higher postprandial VLDL-TAG 
extraction by skeletal muscle in insulin resistant men compared to BMI and age matched 
controls with the metabolic syndrome (126). However, another study including overweight 
men with insulin resistance could not confirm an increased postprandial muscle TAG 
extraction, despite elevated TAG concentrations (63). Recently, it was shown that muscle 
VLDL-TAG extraction was significantly greater in men with type 2 diabetes compared with 
nondiabetic men in the fasting state (127). Although the evidence is not conclusive, these 
studies indicate an impaired skeletal muscle TAG metabolism under insulin resistant 
conditions.  
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Skeletal muscle LPL activity  
The expression and activation of muscle LPL plays a major role in skeletal muscle TAG 
extraction. Mice studies showed that skeletal muscle-specific deletion of LPL reduces lipid 
storage and increases insulin signaling in skeletal muscle (128). Additionally, muscle-specific 
LPL overexpression induced muscle insulin resistance, while skeletal muscle LPL knockdown 
showed the reverse effect (129). Although human data is limited, most studies indicate that 
fasting and exercise raises total LPL activity in human skeletal muscle (130,131), but results 
are not consistent (44). Moreover, insulin has been shown to stimulate LPL activity in adipose 
tissue, but does not appear to activate LPL in skeletal muscle (132). It has been hypothesized 
that these divergent tissue-specific LPL responses to insulin would serve to direct 
TAG-derived fatty acids away from muscle and towards the adipose tissue for storage (132).  
In recent years, ANGPTL4 has emerged as an important inhibitor of skeletal muscle 
LPL activity at the post-translational level (46). In line with adipose tissue, mRNA expression 
of ANGPTL4 in human skeletal muscle is markedly increased during fasting (51). This is 
likely mediated via elevated plasma NEFA concentrations (50,133) and this may offset an 
increase in LPL mRNA/protein concentrations. This could lead to a decreased functional 
LPL activity (42). However, the role of skeletal muscle ANGPTL4 in muscle LPL activity 
and insulin resistance in humans remains to be elucidated. 
The fatty acids that are liberated via LPL-mediated lipolysis as well as these from the 
plasma NEFA pool can be taken up into the skeletal muscle via passive diffusion and by 
protein-mediated transport, such as fatty acid translocase CD36, FABPm and FATP1-6 
(68,134). Of these fatty acid transporters, CD36 is the best characterized. In humans, it was 
shown that CD36 protein expression may be acutely upregulated by insulin (135) and this 
upregulation may be more pronounced in insulin resistant conditions (136). Moreover, 
increased rates of fatty acid transport have been associated with increased localization of 
CD36 at the plasma membrane in individuals with type 2 diabetes, while total CD36 protein 
expression was not changed (137). This suggest that a permanent redistribution of CD36 to 
the plasma membrane occurred, which might play an essential role in the increased skeletal 
muscle uptake.   
Skeletal muscle lipid synthesis  
Once fatty acids have entered the myocyte, they bind to the cytoplasmic FABPc for transport 
through the cell (138). The enzyme long chain fatty acyl-CoA synthetase (LC-FACS) will 
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catalyze their binding to acetyl CoA. Subsequently, they can either be directed towards storage 
in lipid droplets or they can be directed towards the mitochondria to be used as energy source.  
Intramyocellular storage of lipids is part of lipid turnover and is regulated by several 
processes. This includes enzymes catalyzing the esterification of fatty acyl-CoA into TAG 
and lipolytic enzymes. Initiation of TAG synthesis requires coupling of fatty acids to a glycerol 
backbone. The subsequent steps are dependent on the rate limiting enzymes glycerol-3-
phosphatases (GPAT1-4) and diglyceride acyltransferase (DGAT1-2) (29). The latter 
enzyme has a dual role as it promotes TAG storage, but also decreases its precursor DAG 
which has been shown to have an inhibitory effect on insulin signaling in several studies (139). 
Although, there is limited evidence from human studies for a role of DGAT in insulin 
resistance (29), a short-term overexpression of DGAT1 in rat skeletal muscle showed 
beneficial effects on insulin sensitivity, despite increased TAG and DAG concentrations 
(140). Up to now, knowledge on muscle lipid turnover measured in vivo in humans in relation 
to insulin resistance is limited. In insulin resistant smokers compared with less insulin resistant 
non-smokers, muscle TAG concentrations and its fractional synthetic rate were not altered 
(141). Furthermore, a reduced fractional synthetic rate of muscle TAG was found in obese 
pre-diabetic individuals as compared with normal glucose tolerant individuals after exercise. 
This was found together with higher TAG concentrations, a reduced oxidative capacity and 
an impaired peripheral insulin action (142). Notably, these disturbances in muscle TAG 
metabolism were not found in women, indicating sex-related differences in muscle fatty acid 
handling (143). In addition, it was shown that IGT individuals (either isolated or in 
combination with IFG) had a reduced saturation and fractional synthesis of the DAG and 
TAG pool after a high saturated fatty acid mixed-meal (125). In combination with a reduced 
expression of oxidative genes, these data indicate that the insulin resistant muscle is 
characterized by disturbances in lipid turnover, particularly when exposed to a meal high in 
saturated fatty acids.  
Lipid synthesis in skeletal muscle is also controlled by fatty acid desaturation which is 
tightly controlled by the enzyme ∆9-desaturase or steroyl-CoA desaturase 1 (SCD1). It 
desaturates saturated fatty acids into mono unsaturated fatty acids, more specifically stearate 
(C18:0) and palmitate (C16:0) into the less toxic oleate (C18:1n-9) and palmitoleate 
(C16:1n-7) (144). It has been shown that unsaturated fatty acids are the preferred substrates 
for TAG synthesis (145). In rodent myotubes, overexpression of SCD1 resulted in a 
significant increase in fatty acid esterification into TAG, with decreases in fatty acid oxidation 
and accumulation of lipid metabolites such as ceramides. This suggests that SCD1 protects 
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muscle cells from fatty acid induced insulin resistance by reducing ceramide and DAG 
accumulation, at least in rodents (146). However, an increased SCD1 mRNA expression has 
been observed in the skeletal muscle of extremely obese humans with severe muscle insulin 
resistance (147). Therefore, it remains an open question whether SCD1 plays a central role 
in the pathogenesis of insulin resistance.  
Skeletal muscle lipolysis 
Lipid turnover in skeletal muscle is not only determined by TAG synthesis but also by TAG 
lipolysis and subsequent fatty acid oxidation. As in adipose tissue, skeletal muscle lipolysis is 
mainly regulated by insulin and the consecutive action of ATGL and HSL (74,148). An 
in vivo microdialysis study with obese individuals has shown a blunted catecholamine-induced 
lipolysis in skeletal muscle (149). Moreover, obese insulin resistant men have lower HSL and 
higher ATGL protein content in skeletal muscle as well as a reduced HSL mRNA expression, 
phosphorylation and activity (150). This marked difference in muscle lipase content in obese 
insulin-resistant men was accompanied by a lower DAG hydrolase activity, resulting in a 60% 
lower ratio of DAG to TAG hydrolase activity (151). This suggests an incomplete muscle 
TAG hydrolysis. Of interest, this dysbalance in lipase activity was not accompanied by 
increased total DAG accumulation but rather an increase in saturated DAG lipid species in 
the muscle membrane and increased protein kinase C (PKC) activation in men with type 2 
diabetes versus normal glucose tolerant men (151,152). These data together point towards a 
disturbed skeletal muscle lipolysis in obese insulin resistant conditions.  
Fatty acid oxidation in skeletal muscle 
In normal physiology, the aim of skeletal muscle lipid turnover is to provide intracellular fatty 
acids for oxidation when needed. If fatty acids are destined for oxidation, the fatty acyl-CoA 
is transported into mitochondria via the action of carnitine palmitoyl transferase I (CPTI) 
(153). This enzyme is expressed on the outer mitochondrial membrane. Next to CPTI, CD36 
is expressed on mitochondrial membranes and it has been hypothesized to influence 
mitochondrial fatty acid transport and oxidation (154). Once inside mitochondria, fatty acyl-
CoA enters β-oxidation, a process which generates acetyl-CoA for the tricarboxylic acid cycle. 
There, NADH and FADH2 are formed and transferred to the electron transport chain, where 
ultimately the intracellular energy transfer molecule adenosine triphosphate (ATP) is 
produced. This process is called oxidative phosphorylation.  
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An impaired capacity to increase fat oxidation upon increased fatty acid availability and 
to switch between fat and glucose oxidation during insulin-mediated conditions has been 
referred to as metabolic inflexibility (28,155). Under fasting conditions, fatty acid oxidation 
measured across skeletal muscle has been shown to be reduced in obese individuals with type 
2 diabetes (156,157) as well as the postprandial suppression of skeletal muscle fat oxidation 
(120). This apparent inflexibility also included a high reliance of obese individuals on glucose 
oxidation in the fasting state, but this could not be further increased during insulin infusion 
(120). As the absolute rate of lipid oxidation in the obese muscle was not able to change 
between fasting and postprandial conditions, this forms the basis for the ‘metabolic 
inflexibility’ model of skeletal muscle insulin resistance (24,158). 
Mitochondrial dysfunction might be one of the key factors that is responsible for the 
intracellular accumulation of lipids and the inhibition of insulin signaling in skeletal muscle 
(28). This hypothesis is based on links between insulin resistance and decreased ex vivo 
mitochondrial respiration, enzyme activity, fatty acid oxidation (159) and mitochondrial size 
(160). Several studies found low skeletal muscle oxidative capacity in insulin resistant 
individuals (161,162), but results are not consistent (163). Currently, in the scientific 
community there is a large debate ongoing whether the association between mitochondrial 
dysfunction and skeletal muscle insulin resistance is a causal relationship or rather a 
consequence of lipotoxicity (164). 
Lipotoxicity: lipid accumulation in skeletal muscle 
Multiple studies have reported a negative association between intramyocellular lipid (IMCL) 
content and insulin sensitivity in sedentary lean, obese and type 2 diabetes individuals 
(165,166). However, this association is not present in endurance trained athletes who also 
have high levels of IMCL, but also are very insulin sensitive (167). This paradox lead to the 
hypothesis that not IMCL per se, but rather lipid intermediates, like long-chain fatty acyl-
CoAs (LCFA-CoAs), DAG and ceramides, and their localization and fatty acid composition 
are related to insulin resistance. They may interfere in the insulin signaling pathway and 
negatively affect mitochondrial function (29).  
LCFA-CoAs are the metabolically activated form of intracellular fatty acids and it 
commits the fatty acids to either lipid synthesis or fatty acid oxidation in the mitochondria. 
Several data support a link between LCFA-CoAs and insulin resistance. In rodents, studies 
utilizing lipid infusion (168) and high-fat diets (169) have demonstrated increased skeletal 
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muscle LCFA-CoAs in conjunction with insulin resistance. In humans, weight loss reduces 
skeletal muscle LCFA-CoA content in obesity, concomitant with improvements in insulin 
sensitivity (170). Although associations with insulin resistance have been described, so far no 
mechanism by which LCFA-CoA causes insulin resistance have been identified. It is possible 
that LCFA-CoA acts as a precursor for DAG or ceramide synthesis, resulting in insulin 
resistance (171). 
In skeletal muscle, increased DAG concentrations are associated with insulin resistance 
(29). DAG is an intermediate in TAG synthesis and breakdown and it is an important 
intracellular second messenger. Induction of insulin resistance in healthy lean individuals by 
lipid infusion resulted in increased DAG levels in skeletal muscle (172), while weight loss or 
exercise interventions decreased intramuscular DAG concentrations and improved insulin 
sensitivity (173,174). Nevertheless, the role of DAG in this process is controversial (171). It 
has also been proposed that it is not total DAG content per se but rather specific DAG-
subspecies (175,176) or DAG intracellular localization (152,177) that drives insulin resistance 
in humans.  
Ceramides, which belong to the sphingolipid class, are frequently associated with insulin 
resistance as well. Accumulation of ceramides can impair insulin signaling resulting in an 
inhibition of GLUT-4 translocation (178). Indeed, elevated skeletal muscle ceramide levels 
have been observed in in obese insulin-resistant individuals (179-182), but not all studies show 
this association (183,184). Like DAG, it has recently been postulated that specific ceramide-
subspecies might play a more central role in driving insulin resistance rather than total 
ceramide content (185,186). Moreover, diet composition plays a role in skeletal muscle lipid 
composition as well. For instance, it has been shown that increased levels of the saturated fatty 
acid palmitate can drive ceramide synthesis (187). Nevertheless, it remains an open question 
whether ceramides play a central role in the pathogenesis of insulin resistance. 
Outline of the thesis 
Research in this thesis focused on multiple aspects of lipid metabolism in relation to whole-
body and tissue-specific insulin resistance.  
As indicated in this introduction, the obese insulin resistant state is characterized by lipid 
overflow. This is mainly driven by an impaired lipid buffering capacity, and an impaired 
capacity to increase muscle fat oxidation upon increased supply. However, little knowledge is 
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available on the contribution of dietary versus endogenous fatty acids to lipid overflow, their 
extraction and uptake by skeletal muscle as well fractional synthetic rate, content and 
composition of the skeletal muscle lipid pools in insulin resistance. In addition, previous 
studies have used a relatively small sample size due to methodological difficulties as well as 
the high costs associated with using stable isotope tracers. Therefore, in chapter 2 we studied 
the contribution of endogenous and dietary fatty acid sources to skeletal muscle uptake and 
storage in a study of overweight or obese participants (n = 74) with a wide range of insulin 
resistance. We used a combination of differential stable isotope labeling of endogenously 
([2H2]-palmitate) and meal-derived fatty acids ([U-13C]-palmitate tracers) in combination 
with arterio-venous tracee and tracer concentration measurements across forearm muscle and 
biochemical analysis in muscle biopsies.  
Chylomicron- and VLDL-TAG are hydrolysed in the process of intravascular lipolysis 
by LPL. Insulin is an important regulator of LPL activity, but a considerable part of the 
variation in LPL activity may also be explained by other factors. The LPL inhibitor 
ANGPTL4 is an interesting candidate and might be involved in the altered skeletal muscle 
TAG extraction previously observed in insulin resistant conditions. Hence, in chapter 3, the 
role of plasma ANGPTL4 in skeletal muscle lipid metabolism in overweight or obese insulin 
resistant individuals was studied. We investigated the relationship between plasma 
ANGPTL4 concentration and in vivo skeletal muscle LPL activity, but we also addressed the 
impact of dietary fat quality on plasma ANGPTL4 concentrations and examined whether 
human forearm muscle secretes ANGPTL4.  
In addition to skeletal muscle, the role of plasma ANGPTL4 in relation to in vivo 
adipose tissue fatty acid metabolism in humans is currently unknown. Limited information is 
available on the role of ANGPTL4 in the impaired adipose tissue TAG extraction as observed 
in obese individuals in the postprandial state and whether weight loss affects in vivo adipose 
tissue LPL activity and ANGPTL4 in parallel. In chapter 4, the aim was to investigate fasting 
and postprandial plasma ANGPTL4 concentrations and their relationship with in vivo 
adipose tissue LPL activity and intracellular lipolysis in overweight and obese humans before 
and after diet-induced weight loss.   
Although the development of type 2 diabetes and cardiometabolic risk is tightly coupled 
to insulin resistance, there are indications that insulin resistance may not develop 
simultaneously in different organs. For instance, in prediabetes, the IFG phenotype may be 
merely characterized by hepatic insulin resistance, whilst the IGT phenotype has more 
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pronounced peripheral (muscle) insulin resistance. To obtain more evidence for intervention 
strategies targeting different tissue-related or prediabetic phenotypes, more knowledge on the 
distinct phenotypes is required. In chapter 5, we studied cross-sectional associations of tissue-
specific insulin resistance with plasma lipidome profiles. We identified 140 lipid species which 
were measured by liquid chromatography-mass spectrometry. Tissue-specific insulin 
resistance was estimated based on a 0-120 min oral glucose tolerance test with 5 time-points. 
This was studied in a relatively large group of overweight or obese individuals within the 
context of the European multicenter DiOGenes dietary intervention study. Furthermore, in 
chapter 6, in the same cohort, we investigated abdominal subcutaneous adipose tissue 
transcriptome by means of RNA sequencing in relation to tissue-specific insulin resistance.  
Finally, in chapter 7 the main findings from the studies described in this thesis are 
integrated and discussed in a broader perspective and implications for future research are 
provided.  
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Abstract 
Introduction/ hypothesis Disturbances in skeletal muscle fatty acid (FA) handling may 
contribute to the development and progression of whole-body insulin resistance (IR). In this 
study, we compared fasting and postprandial skeletal muscle FA handling in individuals with 
varying degrees of IR. 
Methods Seventy-four overweight/obese participants (62 men) were divided into two groups 
based on the HOMA-IR median (3.35). Fasting and postprandial skeletal muscle FA 
handling were determined by combining the forearm muscle balance technique with stable 
isotopes. [2H2]-palmitate was infused intravenously to label VLDL-triacylglycerol 
(VLDL-TAG) and NEFA in the circulation, whereas [U-13C]-palmitate was incorporated 
in a high-saturated FA mixed-meal labelling chylomicron-TAG. Skeletal muscle biopsies 
were taken to assess intramuscular lipid content, fractional synthetic rate (FSR) and the 
transcriptional regulation of FA metabolism. 
Results Postprandial forearm muscle VLDL-TAG extraction was elevated in the high-IR vs 
the mild-IR group (AUC0–4h: 0.57 ± 0.32 vs -0.43 ± 0.38 nmol [100 mL tissue]-1 min-1, 
respectively, p = 0.045). Although no differences in skeletal muscle TAG, diacylglycerol, 
NEFA content and FSR were present between groups, the high-IR group showed increased 
saturation of the intramuscular NEFA pool (p = 0.039). This was accompanied by lower 
muscle GPAT1 (also known as GPAM) expression (p = 0.050). 
Conclusions/interpretation Participants with high-IR demonstrated increased postprandial 
skeletal muscle VLDL-TAG extraction and higher saturation of the intramuscular NEFA 
pool vs individuals with mild-IR. These data support the involvement of disturbances in 
skeletal muscle FA handling in the progression of whole-body IR.  
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Introduction 
Systemic lipid overflow, which is driven by adipose tissue dysfunction and impaired skeletal 
muscle lipid handling, is associated with insulin resistance (IR) (1). Increased circulating 
triacylglycerol (TAG) and NEFA concentrations are often found in IR because of impaired 
adipose tissue lipid handling (2-4). This results in an increased lipid supply to other non-
adipose tissues, such as liver and skeletal muscle. Due to an impaired capacity to oxidise fatty 
acids (FAs) (5,6), these lipids may accumulate and interfere with insulin signalling in the liver 
and skeletal muscle (7,8). Over the last decade, it has become clear that the amount of lipids 
per se does not determine IR. Rather, a complex interplay between FA supply, FA type, 
muscle lipid turnover, subcellular localisation and composition of specific bioactive lipid 
metabolites seems to determine skeletal muscle IR (1,8,9). 
The contribution of dietary fat (chylomicron-TAG) and endogenous fat (NEFA and 
VLDL-TAG) to skeletal muscle FA handling is not well understood. Elevated plasma NEFA 
concentrations may result from both expanded fat mass (2) and reduced peripheral clearance 
(5,10). Despite a reduced lipolysis per unit fat mass because of hyperinsulinaemia (11,12), the 
total amount of NEFA released from adipose tissue in the postprandial state seems to be 
elevated in the obese insulin resistant state (13). Furthermore, in situations with plasma 
insulin concentrations comparable to insulin levels achieved during a hyperinsulinaemic-
euglycaemic clamp, the spillover from FAs derived from lipoprotein lipase (LPL)-mediated 
TAG hydrolysis in adipose tissue has been shown to be less suppressed in obese patients with 
type 2 diabetes than in non-obese healthy controls (14). This increase in adipose tissue NEFA 
output might lead to increased hepatic VLDL-TAG production and elevated plasma TAG 
concentrations (15,16). Bickerton et al. (17) demonstrated that dietary FAs were preferentially 
taken up in adipose tissue and skeletal muscle in the postprandial state in healthy lean humans, 
even though VLDL particles were abundantly present after the meal (11). 
Up to now, most studies investigating combined VLDL- and chylomicron-TAG 
metabolism have been performed in healthy, lean humans (17,18). Bickerton et al. (11) have 
shown elevated postprandial plasma VLDL- and chylomicron-TAG concentrations in 
overweight men with IR (11). Moreover, we have recently demonstrated that an increased 
postprandial VLDL-TAG extraction was associated with IR in men with the metabolic 
syndrome (19). However, studies involving the combined assessment of human skeletal 
muscle VLDL- and chylomicron-TAG metabolism, and intramuscular lipid species are 
limited. In addition, previous studies have used a relatively small sample size due to 
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methodological difficulties as well as the high costs associated with these measurements. 
Therefore, extensive human in vivo data on skeletal muscle FA handling in IR is currently 
lacking. The aim of this study was to investigate fasting and postprandial skeletal muscle FA 
handling in a large study cohort of overweight or obese participants with a wide range of IR. 
A dual stable isotope tracer technique using labelled palmitate in combination with 
measurements of differences in arteriovenous concentrations across forearm muscle and 
forearm blood flow was used in this study, as previously validated (17). This enabled us to 
differentiate between the metabolic fate of dietary and endogenous FA. In addition, skeletal 
muscle biopsies were taken to investigate skeletal muscle lipid metabolites, their fractional 
synthetic rates (FSRs) and the transcriptional regulation of FA metabolism. 
Methods 
Study participants 
Seventy-four participants (62 men and 12 women) with the metabolic syndrome or impaired 
glucose metabolism were obtained from the Maastricht biobank. These participants 
(described elsewhere in more detail (19-21)) underwent a high-saturated FA (SFA) mixed-
meal test. Participants were divided into two groups based on the median of HOMA-IR 
(3.35); participants below the median of HOMA-IR formed the ‘mild-IR’ group (n = 37) and 
participants above the median formed the ‘high-IR’ group (n = 37). The local Medical Ethical 
Committee of Maastricht University Medical Center+ approved the study protocols. All 
participants gave their written informed consent before participation. 
High-fat mixed-meal test 
Participants were studied after an overnight fast and were asked to refrain from strenuous 
exercise and drinking alcohol for 24 h before the study day. In addition, they were asked to 
avoid food products naturally enriched with 13C for 7 days before the study day. Forearm 
muscle metabolism was studied using arteriovenous concentration differences combined with 
measurements of forearm blood flow. Three catheters were inserted before the start of the 
experiment. One catheter was placed retrogradely into a superficial dorsal vein of a hand 
heated in a hot-box (60°C) to obtain an arterialised blood sample. In the same arm another 
catheter was placed in an antecubital vein for the infusion of the [2H2]-palmitate tracer. A 
third catheter was placed retrogradely in a deep antecubital vein of the contralateral forearm 
to sample venous blood draining the forearm muscle. After taking an arterialised and 
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deep-venous background sample at 90 min before meal ingestion, a continuous intravenously 
infusion of the stable isotope tracer, [2H2]-palmitate (97% enrichment; Cambridge Isotope 
Laboratories, Andover, MA, USA) complexed to albumin was started (0.035 μmol [kg body 
weight]-1 min-1). Baseline blood sampling was started after 1 h of tracer infusion to allow for 
isotopic equilibration to occur. Blood samples were taken simultaneously from the dorsal hand 
vein and the deep muscle vein at three time points during fasting. Samples were also taken at 
six time points postprandially after consumption of a high-SFA mixed-meal (at ‘0 min’) 
containing 200 mg [U-13C]-palmitate (98% enrichment; Cambridge Isotope Laboratories). 
The liquid meal provided 2.6 MJ energy, consisting of 61 energy % (E%) fat (35.5 E%, SFA; 
18.8 E%, monounsaturated FA [MUFA]; 1.7 E% polyunsaturated FA [PUFA]), 33 E% 
carbohydrates and 6.3 E% protein. Analysis of forearm blood flow before blood sampling and 
details of other biochemical analyses have been described previously (19). 
Skeletal muscle biopsies 
Skeletal muscle biopsies were obtained from the vastus lateralis muscle after local anaesthesia 
of the skin and fascia using the Bergström method with suction (22). Muscle biopsies were 
taken during fasting and at the end of the postprandial period (240 min). Muscle biopsies 
were lyophilised and dissected free of extramyocellular lipid, blood and connective tissue under 
a microscope. Details of lipid extraction and quantification have been described previously 
(19). Skeletal muscle expression of genes related to transcription factors, oxidative 
metabolism, lipid synthesis and lipolysis were analysed. Gene expression was normalised 
relative to the geometric mean of the internal reference genes (β-actin, β-2-microglobulin 
and/or ribosomal protein L13a). Details of accession numbers, RNA primer sequences and 
RT-PCR analysis of these genes have been described previously (19,20). Since limited muscle 
biopsy samples were available, not all genes have been measured in all individuals. 
Calculations  
Net fluxes of metabolites (labelled and unlabelled) across the forearm were calculated by 
multiplying the arteriovenous concentration difference by forearm plasma flow. Plasma flow 
was measured using plethysmography and calculated by multiplying forearm blood flow with 
([1 - haematocrit (%vol.)] / 100). A positive flux indicates net uptake across forearm muscle, 
whereas a negative flux indicates net release. Labelled NEFA and TAG concentrations were 
calculated as the product of tracer:tracee ratio (TTR) of [2H2]-palmitate and [U-13C]-
palmitate and the concentration of palmitate in NEFA and TAG, as reported previously (19). 
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The degree of saturation of skeletal muscle TAG, diacylglycerol (DAG), phospholipid 
(PL) and NEFA (%) was calculated by dividing the sum of unsaturated FAs by the total 
amount of FAs in a fraction multiplied by 100. The FSR of skeletal muscle NEFA, TAG, 
DAG and PL was calculated using skeletal muscle NEFA as the precursor pool for lipid 
synthesis. The increase in TTR of [U-13C] from fasting to 4 h postprandial measures was 
divided by the enrichment of skeletal muscle NEFA and expressed as per cent per hour (%/h). 
Postprandial areas under the curve (AUC0– 4h) of metabolites were calculated using the 
trapezium rule and in this study data are presented as AUC0– 4h / min. 
Statistics 
In this study, all data are expressed as means ± SEM. Participant characteristics and 
differences in skeletal muscle lipid handling during fasting and postprandial conditions of the 
mild-IR and high-IR group were compared using independent samples t tests. A linear 
regression was performed with HOMA-IR and BMI and sex as co-variates. Variables were 
loge-transformed if the assumption of normality was not met. The data were analysed using 
SPSS for Mac version 22.0 (SPSS, Chicago, IL, USA) and statistical significance was set at 
p < 0.05. 
Results 
Study population 
Participant characteristics are summarised in Table 1. Age, waist:hip ratio and blood pressure 
were comparable between groups, while BMI was significantly higher in the high-IR group 
(p < 0.002). By design, mean HOMA-IR was different between the two groups (mild-IR vs 
high-IR: 2.5 ± 0.1 vs 4.7 ± 0.3, respectively, p < 0.001). 
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Table 1. Characteristics of participants 
Characteristic Mild-IR (n = 37) 
High-IR 
(n = 37) 
Total group 
(n = 74) 
Range 
(n = 74) p value
a 
Male (n)/Female (n) 33 / 4 29 / 8 62 / 12   
Age (y) 58.0 ± 1.4 59.0 ± 1.1 58.5 ± 0.9 36 – 70   0.582 
Body weight (kg) 89.8 ± 1.9 95.1 ± 2.1 92.5 ± 1.4 64.0 – 115.0   0.064 
BMI (kg/m2) 29.2 ± 0.5 31.7 ± 0.6 30.5 ± 0.4 22.7 – 39.5   0.002 
Waist:hip ratio 1.02 ± 0.01 1.03 ± 0.01 1.02 ± 0.01 0.89 – 1.17   0.494 
Systolic blood pressure (mmHg) 135 ± 2 136 ± 2 135 ± 2 105 – 174   0.636 
Diastolic blood pressure (mmHg) 84 ± 2 85 ± 1 85 ± 1 68 – 110   0.944 
Fasting plasma glucose (mmol/L) 5.4 ± 0.1 5.7 ± 0.1 5.5 ± 0.1 4.6 – 6.7   0.002 
Fasting plasma insulin (pmol/L) 72.3 ± 2.4 130.2 ± 6.6 101.2 ± 4.9 50 – 263.3 < 0.001 
Fasting plasma NEFA (μmol/L) 561 ± 22 598 ± 26 580 ± 17 296 – 1002   0.287 
Fasting plasma TAG (μmol/L) 1320 ± 103 1246 ± 85 1283 ± 66 415 – 3232   0.582 
HOMA-IR 2.5 ± 0.1 4.7 ± 0.3 3.6 ± 0.2 1.68 – 11.3 < 0.001 
Values are means ± SEM  
ap value for difference between mild-IR and high-IR group, Student’s t test for unpaired samples 
Arterialised metabolites, forearm muscle metabolism and forearm 
blood flow 
Fasting arterialised plasma glucose (Figure 1A) and insulin (Figure 1B) concentrations were 
significantly higher in the high-IR group than in the mild-IR group (p = 0.002 and p < 0.001, 
respectively) and remained higher throughout the postprandial period (p = 0.035 and 
p < 0.001, respectively). Net glucose uptake across forearm muscle was similar in the high-IR 
and mild-IR groups under fasting conditions, but was significantly lower in the high-IR group 
than in the mild-IR group after meal ingestion (AUC0– 4h 0.59 ± 0.04 vs 0.76 ± 0.07 μmol 
[100 ml tissue]-1 min-1, respectively, p = 0.034), indicating a lower postprandial insulin 
sensitivity in the high-IR group (see Table 2 and Figure 1C). Arterialised fasting plasma 
glycerol concentrations (p = 0.006) and lactate concentrations were significantly higher 
(p = 0.006) in the high-IR group than in the mild-IR group (Table 2). Forearm blood flow 
and glycerol release were similar between the two IR groups, both during fasting and 
postprandial conditions. Moreover, fasting (p = 0.002) and postprandial (p = 0.048) lactate 
release was positively associated with IR (Table 2). 
  
48  | 
 
Chapter 2 
 
 
Figure 1. Arterialised plasma glucose (A) and insulin (B) concentrations and glucose flux (C) 
during fasting (0 min) and after consumption of a high-SFA meal. Black circles, mild-IR group; 
white circles, high-IR group. Student’s t test for unpaired samples showed significant effect of 
group on fasting and postprandial plasma glucose (p = 0.002 and AUC0–4h: p = 0.035, 
respectively), fasting and postprandial plasma insulin (p < 0.001 and AUC0–4h: p < 0.001, 
respectively) and postprandial glucose flux (AUC0–4h: p = 0.034). Values are presented as mean 
± SEM 
Whole-body and forearm muscle NEFA metabolism 
Fasting arterialised NEFA concentrations were similar in the high-IR and mild-IR groups 
(Figure 2A). After the high-SFA meal ingestion, arterialised NEFA concentrations decreased 
to the same extent in both groups and returned to near-baseline values at the end of the 
postprandial period, with no significant differences observed between the groups. 
[2H2]-palmitate was infused intravenously and was mixed with the plasma NEFA pool. The 
TTR reached steady state during fasting measurements (Figure 2C,D). Consistent with these 
findings, the rate of appearance of NEFA (RaNEFA) decreased after the meal (Figure 2B), 
which is an indication of suppression of whole-body lipolysis. A reduction in postprandial 
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Figure 2. Postprandial whole-body NEFA metabolism. Arterialised plasma NEFA 
concentrations (A), RaNEFA (B), and the TTR of [2H2]-palmitate (C) and [U-13C]-palmitate 
(D) in the plasma NEFA fraction during fasting (0 min) and after consumption of a high-SFA 
meal. Black symbols, mild-IR group; white symbols, high-IR group; in (C) and (D) circles, 
arterialised plasma concentrations and triangles, forearm venous plasma concentrations. Values 
are presented as mean ± SEM 
 
suppression of the RaNEFA was observed in the high-IR group compared with the mild-IR 
group, although the difference did not reach statistical significance (p = 0.079, Figure 2B). 
There were no differences in arterialised concentrations of [2H2]-palmitate and 
[U-13C]-palmitate in NEFA between groups (data not shown). 
The TTR of [2H2]-palmitate in NEFA was higher in arterialised vs deep-venous plasma 
at all time points in both groups. This reflects dilution of the 2H2 tracer in the plasma NEFA 
pool across forearm muscle. The TTR of [U-13C]-palmitate in NEFA (resulting from 
spillover of FA derived from chylomicron-TAG hydrolysis) was not different in arterialised 
vs deep-venous plasma at all time points in both groups (Figure 2C,D). 
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Table 2. Fasting and postprandial lipid metabolism 
Variable Mild-IR High-IR p valuea SE β p valueb 
Forearm blood flow (mL [100 ml tissue]-1 min-1) 
  Fasting 2.5 ± 0.2 2.5 ± 0.2 0.896 0.054   0.682 
  Postprandial 2.6 ± 0.2 2.8 ± 0.2 0.476 0.118   0.369 
Glycerol (μmol/L)      
  Fasting  84.6 ± 3.9 118.5 ± 11.1 0.006 0.200   0.090 
  Postprandial  64.9 ± 3.6 92.9 ± 10.6 0.016 0.278   0.025 
Lactate (μmol/L)      
  Fasting  0.62 ± 0.04 0.79 ± 0.05 0.006 0.438 < 0.001 
  Postprandial 0.98 ± 0.05 1.10 ± 0.05 0.081 0.224   0.087 
Net flux across forearm muscle      
  Glucose (μmol [100 mL tissue]-1 min-1) 
    Fasting  0.23 ± 0.05 0.17 ± 0.03 0.274 -0.083   0.524 
    Postprandial  0.76 ± 0.07 0.59 ± 0.04 0.034 -0.147   0.226 
  Glycerol (nmol [100 mL tissue]-1 min-1) 
    Fasting  -28.3 ± 5.5 -27.0 ± 7.7 0.883 0.224   0.092 
    Postprandial -20.4 ± 4.5 -25.2 ± 6.5 0.541 0.081   0.543 
  Lactate (nmol [100 mL tissue]-1 min-1) 
    Fasting  -0.18 ± 0.02 -0.12 ± 0.03 0.123 0.384   0.002 
    Postprandial  0.01 ± 0.02 0.04 ± 0.03 0.472 0.249   0.048 
  NEFA (nmol [100 mL tissue]-1 min-1) 
    Fasting  -6.9 ± 20.4 26.6 ± 24.6 0.300 0.165   0.210 
    Postprandial  -0.8 ± 9.5 8.7 ± 13.4 0.565 0.112   0.405 
  [2H2]-palmitate NEFA (nmol [100 mL tissue]-1 min-1) 
    Fasting  1.69 ± 0.12 1.58 ± 0.14 0.539 0.017   0.902 
    Postprandial  1.50 ± 0.09 1.53 ± 0.14 0.846 0.171   0.208 
  TAG (nmol [100 mL tissue]-1 min-1) 
    Fasting  10.2 ± 13.2 45.5 ± 12.1 0.052 0.094   0.466 
    Postprandial  53.9 ± 17.2 51.9 ± 28.4 0.954 -0.105   0.422 
continued on next page 
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Table 2. Fasting and postprandial lipid metabolism (continued) 
Variable Mild-IR High-IR p valuea SE β p valueb 
(Net flux across forearm muscle) 
  [2H2]-palmitate TAG (nmol [100 mL tissue]-1 min-1) 
    Fasting  -0.24 ± 0.16 0.56 ± 0.41 0.069 0.241 0.076 
    Postprandial  -0.43 ± 0.38 0.57 ± 0.32 0.045 0.294 0.037 
  [U-13C]-palmitate TAG (nmol [100 mL tissue]-1 min-1) 
    Fastingc       
    Postprandial  0.86 ± 0.16 0.66 ± 0.16 0.353 -0.046 0.736 
Values are means ± SEM. Postprandial values are calculated from AUC0–4h. A positive flux indicates net uptake 
across forearm muscle, whereas a negative flux indicates net release. [2H2]-palmitate NEFA fasting and ap value 
for difference between mild-IR and high-IR group, Student’s t test for unpaired samples. bp value for multiple 
linear regression. c[U-13C]-palmitate was given with a meal, hence fasting data is not available. [2H2]-palmitate 
TAG fasting, n = 34; [2H2]-palmitate NEFA postprandial and [U-13C]-palmitate TAG postprandial, n = 33; 
[2H2]-palmitate TAG postprandial (mild-IR), n = 29; [2H2]-palmitate TAG postprandial (high-IR), n = 32. SE β, 
standardised β coefficient for total group for HOMA-IR, adjusted for sex and BMI 
 
Fasting and postprandial net extraction of plasma NEFA across forearm muscle did not 
differ between groups. Furthermore, there was consistent uptake of [2H2]-palmitate across 
forearm muscle during the study period and this was similar in both groups (Table 2). 
Whole-body and forearm muscle TAG metabolism 
Comparable arterialised TAG concentrations between the high-IR and mild-IR groups were 
observed during fasting and postprandial conditions (Figure 3A). The [2H2]-palmitate tracer 
was measurable in plasma TAG from the first baseline sample onwards, reflecting 
incorporation of the intravenously infused tracer into VLDL-TAG (Figure 3B). The 
[U-13C]-palmitate tracer, which was given with the meal, appeared in plasma TAG from 
60 min after meal ingestion, representing chylomicron-TAG in the circulation (Figure 3B). 
During the postprandial period both labelled TAG fractions increased without significant 
differences between groups. 
Fasting net extraction of [2H2]-palmitate TAG across forearm muscle was higher in the 
high-IR group than in the mild-IR group, although the difference did not reach statistical 
significance (p = 0.069). Postprandial net extraction of [2H2]-palmitate TAG was significantly 
elevated in the high-IR group vs the mild-IR group (p = 0.045) (Figure 3C). In line with this, 
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Figure 3. Postprandial whole-body and forearm muscle TAG metabolism. Arterialised plasma 
TAG concentrations (A), [2H2]- and [U-13C]-palmitate concentrations in the plasma TAG 
fraction (B), and the net flux of [2H2]-palmitate TAG (C) and [U-13C]-palmitate TAG (D) 
across forearm muscle during fasting (0 min) and after consumption of a high-SFA meal. A 
positive flux indicates net uptake across forearm muscle, whereas a negative flux indicates net 
release. Black symbols, mild-IR group; white symbols, high-IR group; in (B) circles, 
[2H2]-palmitate TAG and triangles, [U-13C]-palmitate TAG. Student’s t test for unpaired 
samples showed a significant effect of group on postprandial net flux of [2H2]-palmitate TAG 
(AUC0-4h; p = 0.045). Values are presented as mean ± SEM 
 
we found a significant linear association between postprandial net extraction of 
[2H2]-palmitate TAG and HOMA-IR, even after adjustment for BMI and sex 
(standardised β = 0.294; p = 0.037; Table 2). The net extraction of [U-13C]-palmitate TAG 
across forearm muscle could be detected from 60 min onwards and did not differ significantly 
between groups (Table 2, Figure 3D). 
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Intramuscular lipid metabolism 
Skeletal muscle TAG, DAG and NEFA content were comparable between high-IR and 
mild-IR groups (Table 3). The PL content was lower in the high-IR group than in the 
mild-IR group, although the difference did not reach statistical significance (60.5 ± 3.2 vs 
70.2 ± 3.6 μmol / [g dry weight], respectively, p = 0.055). However, there was no significant 
linear association between PL and measures of IR (Table 3). Intramuscular lipid composition 
was different between groups, with a significantly higher degree of saturation in the muscle 
NEFA pool in participants with high-IR compared with those with mild-IR (51.8 ± 2.8% vs 
43.9 ± 2.5%, respectively, p = 0.039), but there was no significant linear association with IR 
(Table 3). This difference was mainly explained by higher percentages of myristic acid (C14:0; 
3.5 ± 0.7% vs 2.1 ± 0.4%, p = 0.078), pentadecyclic acid (C15:0; 4.5 ± 1.5% vs 1.2 ± 0.3%, 
p = 0.038) and tricosylic acid (C23:0; 3.0 ± 1.1% vs 0.8 ± 0.4%, p = 0.064) in the high-IR 
group vs mild-IR group (Figure 4A). Furthermore, the percentage of PUFA in the NEFA 
pool was lower in the high-IR group than in the mild-IR group (13.0 ± 1.1% vs 17.0 ± 1.4%, 
p = 0.034; Table 3). In addition, lipid composition in the intramuscular DAG pool differed 
between high-IR and mild-IR groups (Table 3): in the high-IR group, the percentage PUFA 
was significantly lower (p = 0.022). Linear regression showed a non-significant negative 
association between the percentage of PUFA in the DAG pool and HOMA-IR. 
Furthermore, a higher percentage of MUFA was observed in the DAG pool of the high-IR 
group compared with the mild-IR group (p = 0.052; Table 3). Although the total saturation 
of the lipid content in the DAG pool did not differ between groups (Table 3), the percentage 
of palmitate (C16:0) in the DAG pool of the high-IR group was significantly higher 
compared with that in the mild-IR group (22.1 ± 0.7% vs 24.6 ± 0.8%, respectively, p = 0.024; 
Figure 4B). 
The FSR of skeletal muscle TAG, DAG and PL was comparable between groups 
(Table 3), indicating that a similar proportion of palmitate from the intramuscular NEFA 
pool was directed towards storage after the high-SFA meal. 
Fasting skeletal muscle mRNA expression of genes encoding proteins involved in 
oxidative metabolism, lipid synthesis and lipolysis is shown in Table 4. Skeletal muscle gene 
expression of GPAT1 (also known as GPAM), a gene involved in lipid synthesis, was 
significantly lower (p = 0.050) in the high-IR group than in the mild-IR group, even when 
adjusted for sex and BMI using linear regression analysis (standardised β = -0.666; p = 0.002). 
Furthermore, the expression level of NDUFB5, encoding a subunit of complex I in the 
electron transport chain, tended to be lower in the high-IR vs the mild-IR group (p = 0.062), 
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Table 3. Skeletal muscle lipid content and composition during fasting and the FSR of the 
muscle lipid pools after a high-SFA meal 
Lipid Mild-IR ( n = 35) 
High-IR 
(n = 28) p value
a SE β p valueb 
NEFA      
  Total (μmol/[g dry weight]) 5.9 ± 0.8 4.9 ± 0.8 0.360 -0.058 0.642 
  % SFA  43.9 ± 2.5 51.8 ± 2.8 0.039 0.219 0.112 
  % MUFA 39.1 ± 1.9 35.2 ± 2.3 0.183 -0.183 0.162 
  % PUFA  17.0 ± 1.4 13.0 ± 1.1 0.034 -0.162 0.266 
  FSR (%/h) 0.38 ± 0.05 0.36 ± 0.07 0.747 -0.069 0.619 
DAG      
  Total (μmol/[g dry weight]) 10.8 ± 2.8 6.2 ± 0.7 0.151 -0.195 0.160 
  % SFA  37.8 ± 1.9 36.6 ± 0.8 0.594 -0.093 0.535 
  % MUFA 44.2 ± 1.6 47.6 ± 0.6 0.052 0.255 0.086 
  % PUFA  18.0 ± 0.8 15.7 ± 0.5 0.022 -0.271 0.059 
  FSR (%/h) 0.33 ± 0.05 0.29 ± 0.05 0.538 -0.058 0.692 
TAG      
  Total (μmol/[g dry weight]) 182.6 ± 24.3 232.1 ± 42.5 0.301 0.126 0.365 
  % SFA  36.7 ± 0.9 35.8 ± 0.9 0.477 -0.157 0.273 
  % MUFA 47.9 ± 1.0 50.1 ± 0.7 0.076 0.046 0.749 
  % PUFA  15.3 ± 0.8 14.1 ± 1.0 0.325 0.112 0.444 
  FSR (%/h) 0.28 ± 0.05 0.21 ± 0.04 0.325 -0.186 0.209 
PL      
  Total (μmol/[g dry weight]) 70.2 ± 3.6 60.5 ± 3.2 0.055 -0.155 0.260 
  % SFA  41.3 ± 0.8 40.4 ± 0.6 0.364 -0.046 0.754 
  % MUFA 11.3 ± 0.3 11.4 ± 0.5 0.903 0.017 0.909 
  % PUFA  47.4 ± 1.0 48.2 ± 0.7 0.496 0.030 0.838 
  FSR (%/h) 0.10 ± 0.01 0.09 ± 0.01 0.486 -0.006 0.966 
Values are means ± SEM. ap value for difference between mild-IR and high-IR group, Student’s t test for unpaired 
samples. bp value for multiple linear regression. SE β, standardised β coefficient for total group for HOMA-IR, 
adjusted for sex and BMI 
 
whilst the expression of the intracellular lipase gene ATGL (also known as PNPLA2) tended 
to be higher in the high-IR group (p = 0.052). 
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Figure 4. Intramuscular NEFA (A), DAG (B), TAG (C) and PL (D) composition under fasting 
conditions. Black bars, mild-IR group; white bars, high-IR group. *p < 0.05, mild-IR vs high-
IR group, Student’s t test for unpaired samples. Values are presented as mean ± SEM 
Discussion 
The present study demonstrated that postprandial forearm muscle VLDL-TAG extraction 
was elevated in individuals with high-IR compared with mild-IR. This elevation in 
VLDL-TAG extraction was accompanied by increased saturation of the intramuscular 
NEFA pool. Both effects were independent of BMI. These data support the notion of an 
important role for disturbances in skeletal muscle FA handling in the progression of whole-
body IR. 
Disturbances in skeletal muscle FA handling have been implicated in the aetiology of IR 
and type 2 diabetes (1,23). Our group has recently demonstrated that higher postprandial 
plasma TAG concentrations and increased net TAG extraction across forearm muscle were 
accompanied by decreased postprandial insulin sensitivity in participants with impaired 
glucose metabolism compared with normal glucose tolerance (24). Furthermore, we showed 
a higher postprandial VLDL-TAG extraction by skeletal muscle in men with IR compared  
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Table 4. Fasting skeletal muscle gene expression 
Gene Mild-IR High-IR p valuea SE β p valueb 
Oxidative metabolism n = 32 n = 30    
  mCPT1B 1.70 ± 0.14 1.74 ± 0.13 0.821 0.006 0.986 
  PGC1α (PPARGC1A) 0.51 ± 0.05 0.46 ± 0.04 0.428 0.027 0.847 
  ACC2 1.52 ± 0.14 1.59 ± 0.16 0.741 0.020 0.891 
  SDHB 2.40 ± 0.21 1.97 ± 0.22 0.153 -0.058 0.683 
  NDUFB5 2.67 ± 0.17 2.14 ± 0.23 0.062 -0.243 0.076 
Transcription factors n = 28 n = 23    
  PPARα (PPARA) 1.63 ± 0.16 1.56 ± 0.11 0.743 0.034 0.808 
  PPARδ (PPARD) 0.36 ± 0.04 0.48 ± 0.07 0.114 0.175 0.259 
  SREBP1c (SREBF1) 0.92 ± 0.10 1.12 ± 0.14 0.238 0.028 0.840 
  SREBP2 (SREBF2) 1.43 ± 0.15 1.86 ± 0.23 0.127 0.266 0.216 
  ChREBP (CREBBP) 1.02 ± 0.19 0.99 ± 0.15 0.906 -0.040 0.859 
TAG synthesis n = 10 n = 15    
  GPAT1 (GPAM) 2.55 ± 0.23 1.81 ± 0.25 0.050 -0.666 0.002 
  DGAT1 1.89 ± 0.19 1.77 ± 0.20 0.667 0.079 0.683 
  DGAT2 0.31 ± 0.05 0.25 ± 0.06 0.509 -0.103 0.671 
TAG lipolysis n = 15 n = 8    
  LPL 0.50 ± 0.08 0.62 ± 0.11 0.342 0.018 0.927 
  ATGL (PNPLA2) 1.11 ± 0.17 2.52 ± 0.60 0.052 0.522 0.007 
  HSL (LIPE) 0.44 ± 0.19 0.74 ± 0.21 0.329 0.130 0.515 
Values are means ± SEM. ap value for difference between mild-IR and high-IR group, Student’s t test for unpaired 
samples. bp value for multiple linear regression. mCPT1b, muscle CPT1B; SE β, standardised β coefficient for 
total group for HOMA-IR, adjusted for sex and BMI 
 
with controls with the metabolic syndrome, matched for age and BMI, despite a similar TAG 
supply (19). More recently, we demonstrated that increased muscle VLDL-TAG extraction 
and reduced lipid turnover of SFA, rather than DAG content, accompany the more 
pronounced IR observed in humans with impaired glucose tolerance (IGT) compared with 
impaired fasting glucose (IFG) (20). 
The present data extend our previous observations regarding FA handling by showing 
that postprandial forearm muscle VLDL-TAG extraction was elevated in participants with 
  
|  57 Skeletal muscle fatty acid handling in IR 
high-IR when compared with those with mild-IR. We included participants who 
encompassed the entire spectrum of insulin sensitivity, from insulin-sensitive to very-insulin-
resistant states (HOMA-IR, 1.7–11.3) and with a wide range of adiposity (BMI, 
22.7-39.5 kg/m2). This allowed us to differentiate between the effect of obesity and IR per se, 
and our present findings confirm those of previous studies that have suggested the existence 
of a relationship between impaired skeletal muscle FA handling and IR (1,8,25). Moreover, 
our data imply that IR is primarily responsible for increased postprandial forearm muscle 
VLDL-TAG extraction, since we observed a significant linear association between VLDL-
TAG extraction and IR. A potential mechanism for increased skeletal muscle VLDL-TAG 
extraction in participants with high-IR may involve differential apolipoprotein composition 
of the VLDL particles (16). For example, higher plasma apoCII:apoCIII ratios  have been 
shown in diabetic individuals, compared with a control group (26). This variation in lipid 
composition might lead to higher a susceptibility for lipid degradation by in vivo skeletal 
muscle LPL (27). Of note, we did not perform measurements in the late postprandial phase. 
It has been shown that dietary FAs appear in VLDL-TAG from 2–3 h after meal ingestion, 
making it difficult to separate chylomicron- and VLDL-TAG in the late postprandial phase 
using the current dual isotope approach (17,28,29). Therefore, we cannot exclude the 
possibility that the increased TAG extraction observed in high-IR participants may also 
extend to chylomicron-TAG. In this context, an impaired inhibitory effect of insulin on 
skeletal muscle LPL action in the high-IR group (30), or impaired FA uptake via membrane-
associated carrier proteins like CD36 (31) might possibly explain the observed differences. 
In addition to an increased skeletal muscle lipid uptake, we observed differences in the 
intramyocellular FA partitioning between groups. Reduced re-esterification of NEFA into 
TAG may expose muscle to excess NEFA concentrations and bioactive lipid metabolites that 
may interfere with insulin signalling (23). In line with this, a reduced incorporation of NEFA 
into TAG in primary myotubes from obese individuals with type 2 diabetes has previously 
been shown (32), indicating that the ability to incorporate FAs into TAG is an intrinsic 
feature of human muscle cells that is reduced in individuals with type 2 diabetes. Moreover, 
in vitro work has shown that muscle cells incubated with palmitate incorporated more FA 
towards the DAG pool, while the unsaturated FAs were diverted towards storage in the TAG 
pool (33). In the present study, an increased percentage of palmitate in the DAG pool in the 
participants with high-IR was observed. Together with the reduced expression of GPAT1, 
which is involved in the first step in TAG synthesis in muscle, this might indicate a retention 
of SFA in the NEFA pool and may explain the lower percentage of PUFA in the DAG pool 
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in the individuals with high-IR vs mild-IR. More recently, we reported a reduced FSR of 
palmitate into intramuscular TAG and DAG in individuals with combined IGT and IFG 
compared with participants with isolated IFG (20). This has also been shown in obese humans 
with impaired glucose metabolism (34). However, in the present study we did not observe 
significant differences between the mild-IR and high-IR groups in the FSR of palmitate into 
intramuscular TAG and DAG. Nevertheless, these findings suggest that the postprandial 
incorporation of FAs in TAG or DAG is not affected by the degree of IR per se. 
Strikingly, in this study the increased saturation in the NEFA pool was mainly confined 
to specific SFAs, namely myristic acid (C14:0), pentadecyclic acid (C15:0) and tricosylic acid 
(C23:0). Recently, plasma odd-chain SFAs were shown to be inversely associated with type 2 
diabetes and coronary heart disease incidence in large epidemiological studies (35). 
Interestingly, dairy products are known to be the most important source for C15:0 (36). This 
would certainly suggest a contribution of dietary fat to the increased saturation of the NEFA 
pool, since it has been shown that FA composition of skeletal muscle reflects dietary FA 
composition (37). However, data related to odd-chain FA metabolism in skeletal muscle is 
currently lacking and more research is needed to unravel the role of odd-chain FAs in 
intramyocellular lipid turnover and skeletal muscle IR. Moreover, it is important to note that 
the increased content of SFA in the high-IR group might be linked to an increased ceramide 
content and higher saturation in the long-chain fatty acyl-CoA. It has been shown that 
increased levels of the SFA palmitate drive ceramide synthesis (38). However, we did not 
measure skeletal muscle ceramide levels or expression of related genes in the present study. 
Finally, previous studies have shown that lower percentages of PUFA in the plasma 
membrane are associated with IR (39,40). However, in this study the percentages of total 
PUFAs in the muscle PL pool were comparable between groups. It is important to note that 
we have not specifically measured muscle membrane PL content but rather total muscle PL 
content. Since most PLs are located mainly in the plasma membrane, the reduced total 
PL content might reflect a lower absolute amount of PUFA in the muscle membrane fraction 
and might therefore contribute to the worsening of IR in individuals with high-IR. 
A limitation of the present study is that we did not perform a hyperinsulinaemic-
euglycaemic clamp test to assess insulin sensitivity. Rather, we divided groups based on a 
surrogate marker of whole-body insulin sensitivity, namely HOMA-IR. Nevertheless, 
previous studies have shown strong correlations between HOMA-IR and peripheral insulin 
sensitivity, as measured by the gold-standard hyperinsulinaemic-euglycaemic clamp (41). 
Importantly, in this study individuals in the high-IR group had a significantly lower 
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postprandial net glucose uptake across forearm muscle as compared with the individuals with 
mild-IR, despite having significantly higher postprandial plasma insulin concentrations. Since 
skeletal muscle accounts for approximately 80% of insulin-mediated glucose uptake in humans 
(42), these data clearly indicate a more pronounced skeletal muscle IR in the individuals with 
high-IR as compared with those with mild-IR. 
In conclusion, increased skeletal muscle VLDL-TAG extraction in the postprandial state 
and higher saturation of the intramuscular NEFA pool are associated with more pronounced 
IR. These data support an important role for disturbances in skeletal muscle FA handling in 
the progression of whole-body IR. 
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Abstract 
Context: Angiopoietin-like protein 4 (ANGPTL4) decreases plasma triacylglycerol (TAG) 
clearance by inhibiting lipoprotein lipase (LPL) and may contribute to impairments in lipid 
metabolism under compromised metabolic conditions. 
Objectives: To investigate the effects of a high-saturated fatty acid (SFA) mixed meal on 
plasma ANGPTL4 concentrations in relation to in vivo muscle LPL activity, to study the 
effects of dietary fat quality, and to examine skeletal muscle ANGPTL4 release. 
Design, Participants, Setting, and Interventions: We used a dual stable-isotope tracer 
technique in combination with measurements of arteriovenous concentration differences 
across forearm muscle to investigate muscle ANGPTL4 secretion and fatty acid handling 
under fasting conditions and after a high-SFA mixed meal in 73 overweight and obese 
humans at the Metabolic Research Unit of Maastricht University. The effect of dietary fat 
quality manipulation on plasma ANGPTL4 was investigated in 10 obese insulin-resistant 
participants. 
Results: The high-SFA meal decreased circulating ANGPTL4 concentrations (fasting, 
5.2 ng/ml vs 4 hours postprandial, 4.0 ng/mL; p < 0.001). Furthermore, skeletal muscle 
ANGPTL4 secretion into the circulation was observed (AUC0–4h, p = 0.048). However, no 
association was observed between plasma ANGPTL4 and skeletal muscle very low-density 
lipoprotein or dietary (chylomicron) TAG extraction (AUC0–4h, p = 0.372 and p = 0.139, 
respectively). In contrast to a high-SFA or high-monounsaturated fat meal, plasma 
ANGPTL4 remained unchanged after a high-polyunsaturated fat meal. 
Conclusions: ANGPTL4 is secreted by human forearm muscle in postprandial conditions 
after a high-SFA meal. Plasma ANGPTL4 concentrations were not associated with in vivo 
skeletal muscle LPL activity after a high-SFA meal. Dietary fat quality affects plasma 
ANGPTL4, but it remains to be elucidated whether this influences short-term skeletal muscle 
lipid handling.   
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Introduction 
Systemic lipid overflow, driven by adipose tissue dysfunction and an impaired skeletal muscle 
lipid handling, may contribute to insulin resistance (1). Lipoprotein lipase (LPL) plays a 
central role in the clearance of triacylglycerol (TAG)-rich plasma lipoproteins (2). LPL is 
located at the capillary endothelium, where it catalyzes the hydrolysis of endogenous very low-
density lipoprotein (VLDL)-TAG and exogenous chylomicron-TAG to glycerol and free 
fatty acids (FFAs) (3). The resulting FFAs are then taken up by the tissues and will be directed 
toward oxidation or storage or will be spilled over into the circulation (4,5). The activity of 
LPL is under tight nutritional and hormonal control. For instance, insulin is a major activator 
of LPL activity (6). Furthermore, angiopoietinlike protein 4 (ANGPTL4) has emerged as an 
important inhibitor of LPL activity, likely by inducing dissociation of catalytically active LPL 
dimers into inactive LPL monomers (7-9). 
The regulation of ANGPTL4 under fasting and postprandial conditions in humans and 
its contribution to human tissue lipid handling is not well understood. Insulin reduces 
circulating ANGPTL4, as revealed by hyperinsulinemic-euglycemic clamps in humans (10-
13). Interestingly, concomitant intravenous infusion of a lipid emulsion high in 
polyunsaturated fatty acids (PUFAs) blunted this insulin-mediated ANGPTL4 decrease. 
This suggests that dietary fat quality might be an important regulator of plasma ANGPTL4 
(10). Furthermore, in vitro studies using human myotubes and adipocytes have shown that 
ANGPTL4 expression and secretion are stimulated by dietary fatty acid quality in a 
peroxisomal proliferator activator receptor-dependent manner (12,14-17). Interestingly, we 
have reported that dietary fat quality affects in vivo skeletal muscle fatty acid handling with 
an increased TAG extraction in obese insulin-resistant humans (18). However, it remains to 
be elucidated whether ANGPTL4 is involved in interindividual differences in skeletal muscle 
lipid metabolism. 
ANGPTL4 is expressed and secreted by numerous cell types, and its expression is 
dependent on nutritional status (19). Human plasma ANGPTL4 concentrations are relatively 
stable, although plasma ANGPTL4 increases after long-term fasting (12,20) and chronic 
caloric restriction (12), as well as following physical activity (12,16,21). These conditions are 
characterized by elevated plasma FFA concentrations. However, the origin of circulating 
ANGPTL4 is currently unknown. Based on human ANGPTL4 mRNA expression and 
ANGPTL4 overexpression studies in mice, it has been postulated that the liver is the main 
contributor to systemic ANGPTL4 concentrations (12,22). In addition, adipose tissue and 
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intestine might also be important contributors to circulating ANGPTL4 concentrations 
(23,24). Interestingly, it has recently been shown that acute exercise induced gene and protein 
expression of ANGPTL4 in skeletal muscle and increased plasma ANGPTL4 concentrations 
(16,21). These data suggest that skeletal muscle might also contribute to plasma ANGPTL4 
(16,21). However, data on in vivo ANGPTL4 secretion by skeletal muscle in humans are still 
lacking. 
The aims of the present study were to investigate the determinants and postprandial 
regulation of plasma ANGPTL4 in overweight and obese prediabetic humans after the intake 
of a high saturated fatty acid (SFA) meal. Secondly, the relationship between plasma 
ANGPTL4 concentration and in vivo skeletal muscle LPL activity was studied. Moreover, 
we addressed the impact of dietary fat quality on plasma ANGPTL4 concentrations and 
examined whether human forearm muscle secretes ANGPTL4 under fasting conditions and 
after the intake of a high-SFA meal. 
Subjects and methods 
Study participants 
In 150 participants (138 men and 12 women), fasting plasma ANGPTL4 concentrations were 
measured. Participants’ characteristics are summarized in Table 1. From this cohort, 
73 participants (61 men and 12 women) with metabolic syndrome or impaired glucose 
metabolism had a high-SFA mixed-meal test. These participants have been described 
elsewhere in more detail (18,25,26). From these participants, 10 obese insulin-resistant men 
also consumed two additional high-fat mixed meals, high in either monounsaturated 
fat (MUFA) or in PUFA (18). The local Medical Ethical Committee of Maastricht 
University Medical Center+ approved the study protocols. All participants gave written 
informed consent before participation. 
High-fat mixed-meal test 
Participants were studied after an overnight fast and were asked to refrain from strenuous 
exercise and drinking alcohol 24 hours before the study day. In addition, they were asked to 
avoid food products naturally enriched with [13C] for 7 days before the study day. Forearm 
muscle metabolism was calculated using arteriovenous concentration differences combined 
with measurements of forearm blood flow. Three catheters were inserted before the start of 
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the experiment. One catheter was placed retrogradely into a superficial dorsal hand vein, 
which was heated in a hot-box (60°C) to obtain an arterialized blood sample. In the same 
arm, another catheter was placed in an antecubital vein for the infusion of the [2H2]-palmitate 
tracer. A third catheter was placed retrogradely in a deep antecubital vein of the contralateral 
forearm to sample venous blood draining the forearm muscle. After taking an arterial and 
deep venous background sample at 90 minutes before meal ingestion (t -90), a continuous 
intravenous infusion of the stable isotope tracer [2H2]-palmitate (97% enrichment; Cambridge 
Isotope Laboratories) complexed to albumin was started (0.035 μmol · kg body weight-1 · min-
1). Baseline blood sampling was started after 1 hour of tracer infusion to allow isotopic 
equilibration to occur. Blood samples were taken simultaneously from the dorsal hand vein 
and the deep muscle vein at three time points during fasting: t -30, t -15, at meal ingestion 
(t 0). They were also taken at six time points postprandially (t 30, t 60, t 90, t 120, t 180, 
t 240) after consumption of a high-SFA mixed meal (t 0) containing 200 mg 
[U-13C]-palmitate (98% enrichment; Cambridge Isotope Laboratories). The liquid meal test 
provided 2.6 MJ, consisting of 61 Energy % (E%) fat (35.5 E% SFA, 18.8 E% MUFA, and 
1.7 E% PUFA), 33 E% carbohydrates, and 6.3 E% protein. Ten obese insulin-resistant 
participants also consumed in a randomized order a liquid high-fat mixed meal (2.6 MJ; 
61 E% fat), which was high in MUFA (42.2 E%) or PUFA (34.8 E%) in a single-blinded 
randomized crossover design (18). Forearm blood flow was measured before each blood 
sampling and has been described previously (27). 
Plasma ANGPTL4 concentration 
ANGPTL4 was measured by ELISA, as described previously (12). Briefly, 96-well plates 
were coated with antihuman ANGPTL4 polyclonal goat IgG antibody (AF3485; R&D 
Systems) and incubated overnight at 4°C. Plates were washed extensively between each step. 
After blocking, 100 μL of 20-fold diluted human plasma was added, followed by 2-hour 
incubation at room temperature. A standard curve was prepared using recombinant 
ANGPTL4 (3485-AN; R&D Systems) at 0.3–2.1 ng/well. Next, 100 μL of diluted 
biotinylated antihuman ANGPTL4 polyclonal goat IgG antibody (BAF3485; R&D 
Systems) was added for 2 hours, followed by the addition of streptavidin-conjugated 
horseradish peroxidase for 20 minutes and tetramethyl benzidine substrate for 6 minutes. The 
reaction was stopped by the addition of 50 μL of 10% H2SO4, and the absorbance was 
measured at 450 nm. Details on other biochemical analyses have previously been 
reported (25). 
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Skeletal muscle ANGPTL4 release and muscle lipid handling 
Net fluxes of ANGPTL4 and metabolites (labeled and unlabeled) across the forearm were 
calculated by multiplying the arteriovenous concentration difference by forearm plasma flow. 
Plasma flow was measured using plethysmography and calculated by multiplying forearm 
blood flow with (1 - hematocrit/ 100). A positive flux indicates net uptake across forearm 
muscle, whereas a negative flux indicates net release. Labeled FFA and TAG concentrations 
were calculated as the product of the tracer-tracee ratio of [2H2]- and [U-13C]-labeled 
palmitate and the concentration of palmitate in FFA and TAG, as reported before (25). 
In vivo LPL activity was based on net fluxes of [2H2]- and [U-13C]-labeled palmitate. 
Postprandial areas under the curve (AUCs) of metabolites were calculated using the trapezium 
rule. Besides the total AUC (0–4 hours after meal ingestion), the “early” (0–2 hours) and 
“mid” (2–4 hours) AUCs were also calculated to obtain more detailed information on the time 
course of the postprandial responses. Likewise, ANGPTL4 changes from baseline (Δ) to the 
“total” (0–4 hours), “early” (0–2 hours), and “mid” (2–4 hours) postprandial phases were 
calculated. 
Statistics 
Correlations between clinical characteristics or postprandial responses and plasma 
ANGPTL4 concentrations were tested by Pearson’s correlation coefficients, partial regression 
analyses, and with multiple linear regression analyses. Repeated-measures ANOVA with time 
as within-subject and dietary fat quality as between-subject factors was performed to identify 
the effects of dietary fat quality on plasma ANGPTL4 concentrations. Student’s unpaired 
t test was used to examine whether ANGPTL4 was released from skeletal muscle into the 
circulation (ANGPTL4 flux vs “zero” flux). The data were analyzed using SPSS for Mac 
version 22.0 (SPSS Inc). Statistical significance was set at p < 0.05, and all data in this study 
are expressed as means ± SEM. 
Results 
Determinants of fasting ANGPTL4 concentration 
First, we investigated determinants of fasting plasma ANGPTL4 concentration in a cross-
sectional study cohort of 150 participants (characteristics in Table 1). Participants had a wide 
range in body mass index (BMI; 20.8 – 49.3 kg/m2) and insulin resistance (homeostasis model 
of assessment for insulin resistance [HOMA-IR], 0.5–11.3). Plasma ANGPTL4 showed a 
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Table 1. Participants’ characteristics 
 Fasting Meal test Dietary fat quality 
No. of participants 
 
150 
 
73 
 
10 
 
Male (n) / Female (n) 
 
138 / 12 
 
61 / 12 
 
10 / 0 
 
Age (y) 
 
55.5 ± 0.8 (23 – 70) 
 
58.6 ± 0.9 (36 – 70) 
 
61.5 ± 1.6 (54 – 70) 
 
BMI (kg/m2) 
 
30.8 ± 0.4 (20.8 – 49.8) 
 
30.5 ± 0.4 (22.7 – 39.5) 
 
33.8 ± 3.8 (28.6 – 38.6) 
 
Waist-hip ratio  
 
1.03 ± 0.01 (0.89 – 1.22) 
 
1.02 ± 0.01 (0.89 – 1.17) 
 
1.04 ± 0.01 (1.00 – 1.10) 
 
Fasting plasma glucose 
(mmol/L) 
5.7 ± 0.1 (4.4 – 8.4) 5.5 ± 0.1  (4.6 – 6.7) 5.6 ± 0.1 (4.8 – 5.6) 
Fasting plasma insulin 
(mU/L) 
14.9 ± 0.5 (2.1 – 38.0) 14.6 ± 0.7 (7.2 – 38.0) 13.7 ± 1.3 (7.8 – 24.1) 
Fasting plasma FFA 
(μmol/L) 
615 ± 16 (127 – 1265) 578 ± 17 (296 – 1002) 652 ± 47 (415 – 846) 
Fasting plasma TAG 
(μmol/L) 
1299 ± 53 (415 – 4571) 1276 ± 67 (415 – 3232) 1204 ± 154 (690 – 2481) 
HOMA-IR 
 
3.7 ± 0.2 (0.5 – 11.3) 3.6 ± 0.2 (1.7 – 11.3) 3.5 ± 0.4 (1.7 – 5.4) 
Fasting plasma 
ANGPTL4 (ng/mL) 
5.7 ± 0.2 (1.2 – 16.4) 5.2 ± 0.2 (2.4 – 11.1) 5.4 ± 0.6 (2.5 – 8.9) 
Values are expressed as mean ± SEM (range) unless specified otherwise. 
 
positive correlation with circulating FFA, fasting insulin, and markers of adiposity, including 
BMI and waist-hip ratio (Table 2). Plasma ANGPTL4 was inversely associated with age and 
fasting glucose. No significant relationship was observed between plasma ANGPTL4 and 
circulating TAG concentrations. A partial regression analysis demonstrated that these 
variables together accounted for 32.7% of the variance in fasting ANGPTL4 
(adjusted R2, 0.327). These results might point toward higher ANGPTL4 concentrations 
when metabolic health is attenuated (Table 2). 
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Table 2. Pearson and partial regression coefficients between fasting plasma ANGPTL4, 
anthropometric and clinical characteristics 
  
R 
 
p-value 
Partial 
regression  
coefficients 
 
p-value 
Age (y) -0.214   0.009 -0.200   0.016 
BMI (kg/m2) 0.420 < 0.001 0.137   0.103 
Waist-hip ratio  0.292 < 0.001 0.167   0.045 
Fasting plasma glucose (mmol/L) -0.185   0.023 -0.318 < 0.001 
Fasting plasma insulin (mU/L) 0.208   0.011 0.149   0.074 
Fasting FFA (μmol/L) 0.355 < 0.001 0.334 < 0.001 
Fasting TAG (μmol/L) -0.041   0.617 -0.202   0.015 
HOMA-IR 0.126   0.123   
High-fat meal intake alters postprandial plasma ANGPTL4 
Next, we investigated the postprandial response of ANGPTL4 in 73 overweight or obese 
participants (characteristics can be found in Table 1), after consumption of a high-SFA meal. 
Arterialized ANGPTL4 concentrations significantly decreased during the postprandial phase 
(baseline, 5.2 ± 0.2 ng/mL, vs 4 hours after meal intake, 4.0 ± 0.2 ng/mL; ANOVA time 
p < 0.001) (Figure 1A). In the present study, fasting plasma FFAs, TAG, insulin, and glucose 
concentrations correlated with fasting plasma ANGPTL4. Therefore we investigated the 
relationship between the postprandial decline in ANGPTL4 concentrations and postprandial 
responses of these circulating factors after a high-SFA meal. Multiple regression analysis 
revealed that postprandial FFA concentration decline (iAUC0–4h) was positively associated 
with the decline in ANGPTL4 (Δ0–4h) after a high-SFA meal (β = 0.002; p = 0.028). This was 
independent from postprandial changes in plasma insulin, glucose, and TAG concentrations. 
Plasma ANGPTL4 does not correlate with muscle LPL activity 
Next, we examined whether fasting plasma ANGPTL4 concentrations or the postprandial 
(changes in) plasma ANGPTL4 concentrations after a high-SFA meal were associated with 
skeletal muscle LPL activity. Using a dual stable isotope methodology, we were able to 
determine forearm muscle TAG extraction from endogenous VLDL-TAG (TAG labeled 
with [2H2]-palmitate) and from chylomicron TAG (TAG labeled with [U-13C]-palmitate), 
as previously reported (5,25). As expected, from the first fasting sample onward, the 
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Figure 1. (A) Plasma ANGPTL4 concentrations (B) Net forearm muscle ANGPTL4 flux 
before and after a high-saturated fatty acid (SFA) meal. Values are mean ± SEM; n = 73. 
 
[2H2]-palmitate tracer could be measured in plasma TAG pool. This reflects the incorporation 
of the intravenously infused tracer into hepatically derived VLDL-TAG. The 
[U-13C]-palmitate tracer (ingested together with the meal), representing exogenous 
chylomicron-TAG, appeared in the plasma TAG fraction 60 minutes after meal ingestion 
(Figure 2A). The net flux of [U-13C]-palmitate in TAG, which reflects LPL-mediated 
hydrolysis of chylomicron-TAG, could be measured from 60 minutes onward until the end 
of the postprandial period (Figure 2B). This was greater than the net flux of [2H2]-palmitate 
in TAG, reflecting VLDL-TAG extraction. There was no relationship between fasting 
plasma ANGPTL4 and baseline VLDL-TAG flux (r = -0.045; p = 0.717) or the postprandial 
plasma ANGPTL4 concentrations and the SFA meal-induced VLDL-TAG flux (AUC0–4h, 
r = 0.117; p = 0.373) and chylomicron-TAG flux (AUC0–4h, r = -0.186; p = 0.139). No gender-
related differences were observed in plasma ANGPTL4 concentrations, VLDL-TAG flux, 
and chylomicron-TAG flux or in the associations between plasma ANGPTL4 and skeletal 
muscle lipid handling. Moreover, when we divided the group into tertiles of [2H2]-palmitate 
and [U-13C]-palmitate skeletal muscle TAG extraction, no differences were observed between 
postprandial plasma ANGPTL4 concentrations (ANOVA p = 0.484 and p = 0.393, 
respectively). These data suggest that plasma ANGPTL4 concentration does not play a major 
role in skeletal muscle fatty acid handling in humans. 
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Figure 2. (A) [2H2]- and [U-13C]-palmitate concentrations in the plasma TAG fraction (B) Net 
flux of [2H2]- and [U-13C]-palmitate TAG across forearm muscle during fasting (t = 0) and after 
consumption of a high-SFA meal. Black symbols, [2H2]-palmitate, n = 61; white symbols, 
dotted line [U-13C]-palmitate, n = 66. Values are mean ± SEM. 
Dietary fat quality affects plasma ANGPTL4 
Next, we investigated the effect of dietary fat quality on fasting and postprandial ANGPTL4 
concentrations and examined postprandial fatty acid handling after meals varying in dietary 
fat quality (18). In 10 obese insulin-resistant participants (characteristics can be found in 
Table 1), plasma ANGPTL4 concentrations decreased after intake of the high-SFA meal 
(baseline, 5.6 ± 0.6 ng/mL; vs 4 hours after meal intake, 4.3 ± 0.4 ng/mL). This decrease was 
also evident after the high-MUFA meal (5.4 ± 0.8 vs 4.8 ± 0.6 ng/mL) but not after a 
high-PUFA meal in the mid postprandial phase (5.1 ± 0.7 vs 5.3 ± 0.6 ng/mL; Δ2–4h p = 0.035) 
(Figure 3). Strikingly, the blunted decrease in plasma ANGPTL4 after the high-PUFA meal 
was accompanied by a lower TAG-derived fatty acid uptake (18).  
ANGPTL4 is released from human skeletal muscle 
Finally, it has been postulated that skeletal muscle may be a source of plasma ANGPTL4 in 
humans (21). In the present study, no significant release of ANGPTL4 from skeletal muscle 
after an overnight fast was found. Importantly, however, significant ANGPTL4 release from 
skeletal muscle was detectable after a high-SFA meal (AUC0–4h; -0.17 ± 0.09 ng ∙ 100 mL 
tissue-1 ∙ min-1 vs zero flux; p = 0.048) (Figure 1B), with the highest release observed in the 
mid postprandial phase (AUC2–4h; -0.26 ± 0.13 ng ∙ 100 mL tissue-1 ∙ min-1 vs zero flux; 
p = 0.045) (Figure 1B). No relationship was found between skeletal muscle ANGPTL4 release 
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Figure 3. ANGPTL4 concentrations during fasting (t = 0) and after consumption of three high-
fat mixed meals. Circles, SFA; squares, MUFA; triangles, PUFA. Values are mean ± SEM, 
n = 10. *, Δ 2–4 h; p < 0.05. 
 
and postprandial insulin sensitivity (AUCglucose ∙ AUCinsulin ∙ 10-6) (p =  0.127), BMI (p = 0.568), 
or waist-hip ratio (p = 0.484). Similarly, when we divided the group into tertiles of 
[2H2]-palmitate and [U-13C]-palmitate TAG extraction, no differences were observed in 
skeletal muscle ANGPTL4 release (ANOVA p =  0.944 and p =  0.895, respectively). 
Discussion 
This study demonstrates that during fasting conditions and after intake of the high-SFA meal, 
plasma ANGPTL4 concentrations were not associated with in vivo skeletal muscle LPL 
activity. Moreover, under physiological postprandial conditions, we found that plasma 
ANGPTL4 was markedly decreased after a high-SFA and high-MUFA meal, but not after 
a high-PUFA meal. Strikingly, this was accompanied by a differential skeletal muscle fatty 
acid handling, with a reduced TAG extraction after the high-PUFA meal compared with the 
high-SFA meal, as reported previously (18). Finally, we demonstrate for the first time that 
ANGPTL4 was released from skeletal muscle into the circulation after high-SFA meal 
ingestion in humans. 
Little is known about the determinants of plasma ANGPTL4. So far, a clear, positive 
relationship with plasma FFA has been shown (12,14,15,20). Here, we demonstrate in a 
group of participants with a broad range in BMI and insulin sensitivity that fasting plasma 
ANGPTL4 is positively related to waist-hip ratio and circulating FFA concentrations. 
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Furthermore, it is negatively related to circulating TAG and glucose concentrations. Overall, 
our data indicate that plasma ANGPTL4 is increased in participants with an attenuated 
metabolic health profile. Indeed, the progression of the metabolic syndrome toward 
type 2 diabetes mellitus has also been shown to increase plasma ANGPTL4 (28). Strikingly, 
after a high-SFA meal, plasma FFAs are the main determinants of circulating ANGPTL4 
independently of insulin, glucose, and TAG, suggesting that FFAs are a key regulator of 
plasma ANGPTL4 in the postprandial state. 
Our current understanding of the physiological role of ANGPTL4 indicates an 
important role in tissue-specific LPL inhibition (19). Nevertheless, we could not show a 
relationship between circulating ANGPTL4 and in vivo skeletal muscle LPL activity during 
fasting conditions and after a high-SFA meal. Importantly, these findings do not exclude the 
possibility that ANGPTL4 is a local regulator of LPL activity via autocrine and paracrine 
actions and that plasma ANGPTL4 does not reflect local effects in skeletal muscle on LPL 
activity. Indeed, tissue-specific LPL activity regulation by ANGPTL4 has been shown to take 
place in the subendothelial space rather than at the endothelium (7,29). In line with these 
findings, it was proposed that newly synthesized and locally produced ANGPTL4 might have 
more pronounced effects on LPL activity than circulating ANGPTL4 (30). Furthermore, 
data from a genetic study with carriers of a rare plasma TAG-lowering genetic variant of 
ANGPTL4, T266M, also suggest that ANGPTL4 at the cell surface rather than circulating 
ANGPTL4 might play a role in LPL inhibition (31). T266M carriers have significantly 
higher plasma ANGPTL4 concentrations compared with T266 carriers, and in vitro studies 
with cultured human cells have shown higher secretion of ANGPTL4 T266M compared with 
wild type. Nevertheless, this ANGPTL4 variant was not associated with plasma TAG (31). 
These data suggest that locally produced ANGPTL4 rather than plasma ANGPTL4 may 
mediate LPL inhibition after a high-SFA meal. Moreover, it is important to note that 
additional factors are involved in functional ANGPTL4 activity. For instance, it has been 
suggested that the locally produced glycosylphosphatidylinositol-anchored high-density 
lipoprotein-binding protein might compete with ANGPTL4 for LPL binding at either the 
interstitial space or capillary lumen (19). This indicates that there is a complex regulation of 
in vivo LPL activity with many factors involved. However, the exact inter-relationships 
remain unclear and need to be investigated in more detail in future research. 
In addition to plasma FFA, dietary fat quality might be an important determinant of 
circulating ANGPTL4. Indeed, the present study found that a high-PUFA meal blunted the 
postprandial ANGPTL4 decline that was observed after a meal rich in SFAs or MUFAs. 
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This was accompanied by a reduced muscle TAG-derived fatty acid uptake (18). It is 
tempting to speculate from these data that ANGPTL4 may play a role in the reduced muscle 
LPL activity after a high-PUFA meal. For instance, it has been shown that incubation of 
murine C2C12 myocytes and human myotubes with long-chain fatty acids induced 
ANGPTL4 expression in a peroxisomal proliferator activator receptor-δ-dependent manner 
(14,16). Furthermore, infusion of lipid emulsions high in MUFA or PUFA under 
hyperinsulinemic conditions blunted the insulin-mediated ANGPTL4 decrease in vivo in 
humans (10). Our findings, together with earlier observations, indicate that meal fatty acid 
composition affects plasma ANGPTL4. However, it remains to be elucidated whether or not 
this finding is important in the previously reported differential effect of dietary fat quality on 
TAG-derived fatty acid uptake in skeletal muscle in vivo. 
The contribution of different tissues to circulating ANGPTL4 concentration remains to 
be established. In the present study, we provide for the first time direct in vivo evidence that 
skeletal muscle contributes to plasma ANGPTL4 in humans. Furthermore, it has been shown 
that basal in vitro ANGPTL4 expression in human myotubes correlated positively with 
plasma ANGPTL4 of the donors (14). Moreover, increased skeletal muscle ANGPTL4 
mRNA and protein expression and plasma ANGPTL4 have been shown after acute exercise 
in humans, indirectly suggesting the contribution of skeletal muscle to circulating ANGPTL4 
(16,21). In our study, the relative muscle-derived contribution to circulating concentrations is 
difficult to estimate because information on ANGPTL4 half-life is lacking. The fact that 
plasma ANGPTL4 concentrations decline postprandially might indicate that skeletal muscle 
is not the major organ regulating postprandial plasma ANGPTL4 concentrations. In 
addition, we could not detect a significant release under fasting conditions, suggesting that 
other tissues such as adipose tissue, liver, and intestine contribute more to fasting plasma 
ANGPTL4 concentrations (16,19). 
This study had some limitations. First, mainly overweight and obese people and/or 
subjects with impaired glucose metabolism were included. Therefore, we cannot exclude that 
the lack of association between in vivo LPL activity and plasma ANGPTL4 may have been 
be due to the absence of a healthy, lean, normoglycemic group. Nevertheless, the participants 
covered a broad range in insulin sensitivity (HOMA-IR, 1.7 – 11.3) and adiposity (BMI, 
22.7 – 39.5 kg/m2). Consequently, the present analyses do not support a major contribution 
of plasma ANGPTL4 concentration in the regulation of in vivo skeletal muscle LPL activity 
in humans. Secondly, we cannot exclude that plasma ANGPTL4 does not accurately reflect 
functional ANGPTL4. Moreover, we have measured full-length ANGPTL4 and the 
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C-terminal truncated fragment, but not the N-terminal truncated fragment of ANGPTL4 
(20). However, both the full-length and the N-terminal fragment ANGPTL4 may influence 
plasma lipid concentration (32). Therefore, it remains to be established whether the results 
from the ANGPTL4 ELISA provide accurate reflection of functional ANGPTL4. Finally, 
in our forearm model, we cannot exclude the possibility that inter- and intramuscular fat 
contamination may have contributed to muscle-derived ANGPTL4 release in this study 
population (33) or the contribution of other cell types such as endothelial cells (34) and 
macrophages (28). However, previous data indicate that adipose tissue contribution is 
minor (27). 
In conclusion, we provide in vivo evidence that ANGPTL4 is secreted from the human 
skeletal muscle after a high-SFA meal. Furthermore, our data indicate that plasma 
ANGPTL4 concentrations do not relate to in vivo muscle LPL activity after a high-SFA 
meal. However, we cannot exclude the possibility that ANGPTL4 could play a local role in 
skeletal muscle lipid metabolism in insulin resistant conditions after a high-SFA meal. Finally, 
we show a postprandial decline in plasma ANGPTL4 after a high-SFA and high-MUFA 
meal, but not after a high-PUFA meal, suggesting that dietary fat quality might regulate 
short-term muscle lipid handling via ANGPTL4. However, the mechanisms involved in the 
regulation of in vivo skeletal muscle LPL activity need to be investigated in more detail in 
future studies. 
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Summary 
Over the last decades, the prevalence of obesity has reached epidemic proportions and obesity 
and its metabolic consequences are major contributors to morbidity and mortality worldwide. 
Obesity is strongly linked to the development of insulin resistance, which in turn is a major 
risk factor in the development of cardiometabolic diseases. Insulin resistance can develop 
simultaneously in multiple organs and severity may vary between organs. Over the years, it 
has been convincingly shown that there is a complex interplay between metabolic insulin 
sensitive organs involved in lipid metabolism, such as adipose tissue, skeletal muscle and liver. 
In addition, impairments in lipid metabolism play an important role in the development and 
progression of insulin resistance. The present thesis therefore aimed to study multiple aspects 
of lipid metabolism in relation to whole-body and tissue-specific insulin resistance using a 
physiological approach. 
In chapter 2 we studied the contribution of endogenous and dietary fatty acid sources to 
skeletal muscle uptake and storage in overweight or obese individuals with a wide range of 
insulin resistance. To study the metabolic fate of dietary versus endogenous fatty acids, a dual 
stable isotope technique was applied. [U-13C]-palmitate was added to a high-saturated fatty 
acid mixed meal to label chylomicron-triacylglycerol (TAG) (i.e. exogenous or dietary TAG) 
in the circulation. Simultaneously, [2H2]-palmitate was infused intravenously to label 
endogenous fatty acids. As [2H2]-palmitate can be incorporated into newly synthesized TAG 
in the liver, [2H2]-labelled TAG reflects very-low-density-lipoprotein (VLDL)-TAG (i.e. 
endogenous TAG) in the circulation. This stable isotope technique was combined with 
measurements of arterio-venous concentration differences across the forearm muscle to 
investigate skeletal muscle fatty acid handling and the specific contribution of the different 
fat sources to skeletal muscle fatty acid handling. We showed that insulin resistance is 
associated with increased postprandial VLDL-TAG extraction across the forearm muscle, 
despite a similar supply of TAG. In addition, distinct patterns of lipid composition were 
observed in the skeletal muscle lipid pools in insulin resistance, as reflected by an increased 
saturation of the intramyocellular non-esterified fatty acid pool. Ultimately, the elevated TAG 
extraction and an altered intramuscular lipid composition may lead to skeletal muscle insulin 
resistance, but exact underlying mechanisms remain to be defined. 
In chapter 3 and 4, we investigated the role of plasma angiopoietin-like protein 4 
(ANGPTL4) in skeletal muscle and in abdominal subcutaneous adipose tissue lipoprotein 
lipase (LPL) activity as reflected by in vivo TAG extraction across these tissues. 
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Chylomicron- and VLDL-TAG are hydrolyzed by LPL in the process of intravascular 
lipolysis and subsequently fatty acids are extracted by underlying tissues. Insulin is an 
important regulator of LPL activity, but a considerable part of the variation in LPL activity 
may also be explained by other factors. The LPL inhibitor ANGPTL4 is an interesting 
candidate and might be involved skeletal muscle and adipose tissue TAG extraction. In 
chapter 3 and 4 we show that plasma ANGPTL4 concentrations were not associated with 
TAG extraction (e.g. a measure for in vivo LPL activity) across the forearm skeletal muscle 
and abdominal subcutaneous adipose tissue. Interestingly, the data we additionally present in 
chapter 4, indicated that plasma ANGPTL4 might play a role in adipose tissue intracellular 
lipolysis after weight loss and therefore possibly in lipid partitioning after weight loss. Finally, 
we provided for the first time in vivo evidence that ANGPTL4 is secreted from the human 
skeletal muscle and adipose tissue after a high-saturated fatty acid mixed meal (chapter 3 and 
4).  
In chapter 5 and 6, we acquired more information on distinct insulin resistant 
phenotypes, which is necessary to develop intervention strategies targeting different tissue-
related or prediabetic phenotypes. Tissue-specific insulin resistance was estimated by using a 
2 hours oral glucose tolerance test, with glucose and insulin measurements at five time-points. 
We included cross-sectional data from the Diet, Obesity and Genes (DiOGenes) project, 
which is a large, multicenter, randomized, controlled dietary intervention study and involved 
eight European countries. In chapter 6, we additionally included individuals from the Cohort 
on Diabetes and Atherosclerosis Maastricht (CODAM). Both cohorts comprised overweight 
and obese non-diabetic individuals who are at risk for developing cardiometabolic diseases. 
In chapter 5, we investigated cross-sectional associations of tissue-specific insulin 
resistance with the plasma lipidome. 140 plasma lipids were quantified by liquid 
chromatography–mass spectrometry. We showed a positive association between muscle 
insulin sensitivity and plasma lysophosphatidylcholine levels in both sexes. Furthermore, we 
identified sex differences in the associations between hepatic insulin resistance and the plasma 
lipidome. Hepatic insulin resistance was higher in men compared to women. However, in 
women an increase of hepatic insulin resistance was associated with an increase in plasma 
TAG and diacylglycerol and a decrease in the relative abundance of odd-chain and very-long-
chain TAG. In contrast, the degree of hepatic insulin resistance did not relate to alterations 
in the plasma lipidome in men. Combined with the observation that overweight/obese women 
had less hepatic insulin resistance and lower TAG levels than men, this would suggest that 
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the plasma lipidome may be more responsive to worsening of hepatic insulin resistance in 
women, or vice versa.  
In chapter 6 we further characterized tissue-specific insulin resistance phenotypes by 
studying the abdominal subcutaneous adipose tissue transcriptome by means of RNA 
sequencing. In individuals with primarily hepatic insulin resistance, extracellular matrix 
remodeling genes (e.g. collagens) were significantly upregulated, whilst in individuals with 
primarily muscle insulin resistance, genes related to inflammation (e.g. chemokines and 
complement activation) were significantly upregulated in abdominal subcutaneous adipose 
tissue. Subsequent analyses in the CODAM cohort showed that an increased systemic 
inflammatory profile compromised of eight plasma inflammatory markers may be specifically 
related to muscle insulin resistance. Based on these findings, we hypothesize that increased 
abdominal subcutaneous adipose tissue inflammatory gene expression in the muscle insulin 
resistant phenotype may translate into an increased systemic inflammatory profile, putatively 
linking subcutaneous adipose tissue inflammation to muscle insulin resistance. 
In conclusion, the results from this thesis show distinct metabolic profiles in non-diabetic 
overweight and obese individuals in relation to (tissue-specific) insulin resistant phenotypes. 
We showed that insulin resistance is associated with increased postprandial VLDL-TAG 
extraction across the forearm muscle, despite a similar supply of TAG. As TAG extraction is 
mediated by LPL in skeletal muscle and adipose tissue, we showed that these results could 
not be explained by plasma levels of the LPL inhibitor ANGPTL4. In addition, a distinct 
lipid composition was observed in the skeletal muscle non-esterified fatty acid pool in insulin 
resistance, which were mainly related to an increased saturation of the intramyocellular non-
esterified fatty acid pool. Finally, we showed distinct plasma lipidome and abdominal 
subcutaneous adipose tissue transcriptome profiles in overweight and obese individuals in 
relation to tissue-specific insulin resistance phenotypes. These unique metabolic profiles 
require further mechanistic exploration and may serve as starting point for developing 
intervention strategies targeting different tissue-related or prediabetic phenotypes. 
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Samenvatting 
De prevalentie van obesitas heeft epidemische vormen aangenomen in de afgelopen decennia. 
Wereldwijd dragen obesitas en de metabole gevolgen ervan op grote schaal bij aan morbiditeit 
en mortaliteit. Obesitas gaat vaak gepaard met de ontwikkeling van insulineresistentie, wat 
op zijn beurt weer een grote risicofactor is voor de ontwikkeling van cardiometabole ziekten. 
Insulineresistentie kan zich in meerdere organen ontwikkelen en de ernst ervan kan varieren 
tussen verschillende organen. In de afgelopen jaren is het overtuigend bewezen dat, als het 
gaat om de vetstofwisseling, er een complexe samenwerking is tussen de verschillende 
metabole insulinegevoelige organen zoals vetweefsel, skeletspier en lever. Vetstofwisseling 
speelt dus een belangrijke rol in de ontwikkeling en het verloop van insulineresistentie. Het 
doel van het huidige proefschrift was daarom om meerdere aspecten van de vetstofwisseling 
in relatie tot insulineresistentie in het gehele lichaam of orgaanspecifiek te bestuderen. Daarbij 
werd gebruikt gemaakt van een fysiologische benadering.  
In hoofdstuk 2 onderzochten we in vivo de afzonderlijke bijdrage van vetten afkomstig 
van voeding (exogene vetten; chylomicronen) en vetten reeds aanwezig in het lichaam 
(endogene vetten; vrije vetzuren en vetten in de vorm van VLDL-deeltjes) aan de vetopname 
en opslag in de skeletspier bij personen met overgewicht of obesitas met een brede spreiding 
in insulineresistentie. Hiertoe gebruikten we twee verschillende stabiele isotopen van het 
vetzuur palmitaat, in combinatie met metingen van arterieel-veneuze concentratieverschillen 
over de onderarmspier. We voegden [U-13C]-palmitaat toe aan een vetrijke milkshake met 
veel verzadigde vetten om chylomicronen te kunnen traceren. Tegelijkertijd infuseerden we 
[2H2]-palmitaat in de bloedbaan om vrije vetzuren en vetten in de vorm van VLDL-deeltjes 
te kunnen traceren. We vonden dat insulineresistentie was geassocieerd met een verhoogde 
extractie van VLDL-triacylglycerol (TAG) over de skeletspier bij insulineresistente personen, 
ondanks gelijke circulerende TAG-concentraties. De absolute hoeveelheid en de incorporatie 
van voedingsvetten in lipidenfracties van de spier (TAG, diacylglycerol, vrije vetzuren en 
fosfolipiden) was niet verschillend. Wel toonden we aan dat de vrije vetzuren fractie in de 
spier van insulineresistente personen een hoger gehalte aan verzadigde vetzuren bevatte. Deze 
data suggereren dat een verhoogde extractie van VLDL-TAG door de skeletspier na een 
maaltijd en een verhoogde verzadiging van de vrije vetzuren fractie in de spier geassocieerd 
zijn met insulineresistentie. Uiteindelijk kunnen deze verhoogde extractie van VLDL-TAG 
en veranderingen in samenstelling van lipidenfracties bijdragen aan de ontwikkeling van 
skeletspier insulineresistentie, maar de precieze onderliggende mechanismen moeten nog 
verder onderzocht worden. 
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In hoofdstuk 3 en 4 onderzochten we de rol van het eiwit angiopoietin-like protein 4 
(ANGPTL4) in lipoprotein lipase (LPL) activiteit in de skeletspier en het abdominale 
onderhuidse vetweefsel. Vetten in de vorm van chylomicronen en VLDL-deeltjes worden 
gehydrolyseerd door het eiwit LPL in de intravasculaire ruimte en de vrijgekomen vetzuren 
kunnen worden geëxtraheerd door de onderliggende weefsels (TAG-extractie). Insuline is een 
belangrijke regulateur van LPL activiteit, maar een deel van de variatie in TAG-extractie kan 
mogelijk ook verklaard worden door andere factoren. De LPL-remmer ANGPTL4 is daarom 
een interessante kandidaat en mogelijk betrokken bij de TAG-extractie in skeletspier en 
vetweefsel. In hoofdstuk 3 en 4 laten we zien dat ANGPTL4-concentraties in het plasma niet 
gerelateerd zijn aan TAG-extractie over de skeletspier en het abdominale onderhuids 
vetweefsel. Aanvullend laten onze data van hoofdstuk 4 zien dat ANGPTL4 in het plasma 
mogelijk gerelateerd is aan intracellulaire lipolyse in het onderhuidse vetweefsel na 
gewichtsverlies. Eventueel kan dit erop wijzen dat ANGPTL4 een rol speelt in de verdeling 
van vetten over het lichaam na gewichtsverlies. Tot slot tonen we in hoofdstuk 3 en 4 voor de 
eerste keer aan dat ANGPTL4 wordt uitgescheiden door de skeletspier en onderhuids 
vetweefsel na een vette maaltijd met veel verzadigde vetten.  
In hoofdstuk 5 en 6 bestudeerden we verschillende weefselspecifieke insulineresistente 
fenotypes in meer detail. We bepaalden weefselspecifieke insulineresistentie met behulp van 
de orale glucosetolerantietest (OGTT), waarbij we gedurende twee uur vijf keer plasma 
glucose en insuline concentraties hebben gemeten. We maakten gebruik van cross-sectionele 
data van het ‘Diet, Obesity and Genes’ (DiOGenes) project. Dit is een groot, gerandomiseerd 
en gecontroleerd dieet interventie onderzoek, uitgevoerd in acht Europese landen. In 
hoofdstuk 6 maakten we aanvullend ook gebruik van cross-sectionele data van het ‘Cohort on 
Diabetes and Atherosclerosis Maastricht’ (CODAM) project. Belangrijk om te vermelden is 
dat beide cohorten bestaan uit personen met overgewicht en obesitas zonder diabetes, maar 
een verhoogd risico hebben op het ontwikkelen van cardiometabole ziekten.   
 In hoofdstuk 5 analyseerden we cross-sectionele associaties tussen weefselspecifieke 
insulineresistentie en het circulerende lipidenprofiel. 140 lipiden werden gekwantificeerd met 
behulp van vloeistofchromatografie met tandem massaspectrometrie (LC-MS). We toonden 
aan dat er een positieve relatie is tussen spier insulinegevoeligheid en lysophosphatidylcholine 
concentraties. Verder lieten we zien dat er geslachtsverschillen zijn in de associaties tussen 
lever insulineresistentie en het circulerende lipidenprofiel. Lever insulineresistentie was hoger 
in mannen dan in vrouwen. Maar we vonden bij vrouwen een relatie tussen een slechtere lever 
insulineresistentie en verhoogde concentraties van plasma TAG en diacylglycerol. Bovendien 
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hadden vrouwen ook een lagere dichtheid van oneven keten vetzuren en zeer lange keten 
vetzuren in TAG als ze een ongezondere lever insulineresistentie hadden. Daartegenover 
vonden we in mannen geen relatie tussen de mate van lever insulineresistentie en 
veranderingen in het lipidenprofiel. Als we deze waarnemingen combineren met de gegevens 
dat vrouwen met overgewicht of obesitas minder lever insulineresistentie hebben en lagere 
plasma TAG-concentraties, dan zou dit kunnen suggereren dat het vetprofiel in de circulatie 
bij vrouwen sneller reageert op een verslechtering van lever insulineresistentie, of vice versa.  
In hoofdstuk 6 hebben we het transcriptoom van het abdominale onderhuidse vetweefsel 
in weefselspecifieke insulineresistente fenotypes gekarakteriseerd. Dit hebben we gedaan met 
behulp van RNA sequencing. In personen met voornamelijk lever insulineresistentie waren 
extracellulaire matrix organisatie genen (bijvoorbeeld collagenen) significant opgereguleerd, 
terwijl genen die gerelateerd zijn aan ontstekingsfactoren waren opgereguleerd in personen 
met voornamelijk spier insulineresistentie, zoals chemokinen en complement factoren. 
Vervolganalyses in het CODAM-cohort lieten zien dat een verhoogd systemisch 
ontstekingsprofiel, bestaande uit acht plasma ontstekingsfactorenmarkers, mogelijk specifiek 
gerelateerd is aan spier insulineresistentie. Daarom hebben we de hypothese opgesteld dat een 
verhoogde genexpressie van ontstekingsfactoren in het abdominale onderhuidse vetweefsel 
kan leiden tot een verhoogd systemisch ontstekingsprofiel in het spier insulineresistentie 
fenotype. Dit kan eventueel de verbinding zijn tussen ontstekingen in het abdominale 
onderhuidse vetweefsel en spier insulineresistentie.  
Concluderend kunnen we zeggen, op basis van de resultaten beschreven in dit 
proefschrift, dat er duidelijke onderscheidende metabole profielen zijn in (weefselspecifieke) 
insulineresistentie in personen met overgewicht en obesitas. We toonden aan dat 
insulineresistentie is geassocieerd met met een verhoogde VLDL-TAG-extractie over de 
onderarmspier na een maaltijd, ondanks gelijke TAG-concentraties in de circulatie. 
Aangezien TAG-extracie door LPL wordt geregeld in de skeletspier en het vetweefsel, lieten 
we ook zien dat bovenstaande resultaten niet verklaard konden worden door plasmawaarden 
van de LPL-remmer ANGPTL4. Verder toonden we aan dat de de vrije vetzuren fractie in 
de spier een hoger gehalte aan verzadigde vetzuren bevatte bij insulineresistente personen. Tot 
slot lieten we zien dat er een onderscheidend plasma lipidoom en abdominale onderhuidse 
vetweefsel transcriptoom zijn in relatie tot weefselspecifieke insulineresistentie in personen 
met overgewicht of obesitas. Deze unieke metabole profielen zullen nog verder onderzocht 
moeten worden, maar kunnen dienen als startpunt voor het ontwikkelen van nieuwe 
interventiestrategieën voor (weefselspecifieke) insulineresistentie of prediabetes. 
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Valorization 
Knowledge valorization is described by the National Valorization Commission as “the process 
of creating value from knowledge, by making knowledge suitable and/or available for societal 
purposes, and suitable for translation into competitive products, services, processes, and new 
commercial activities”. In this addendum we describe how society may benefit from the work 
conducted in this thesis.  
Our research focused on extending fundamental knowledge about the underlying 
multiple aspects of lipid metabolism in relation to whole-body and tissue-specific insulin 
resistance. The main outcomes of the present thesis can serve as starting point for further 
characterization of different tissue-specific insulin resistant or prediabetic phenotypes. 
Ultimately, this may provide directions for more targeted and personalized intervention 
strategies. The valorization potential of these studies will be described in terms of social and 
economic relevance of obesity research, relevance of measurements for targeted prevention 
and innovation and translation into practice.  
Social and economic relevance of obesity research 
The prevalence of obesity has risen to epidemic proportions over the last decades and affects 
people of all ages and socioeconomic groups (1). More than 39% of the world adult population 
was overweight (BMI > 25 kg/m2) and about 13% was obese (BMI > 30 kg/m2) in 2014 (2). 
In 2015, in the Netherlands, over 50% of the individuals over 20 years of age were overweight 
or obese (3).  
The increasing prevalence of obesity is a major health concern. Obesity increases the risk 
for developing chronic diseases such as type 2 diabetes, cardiovascular diseases, mental 
disorders, several cancer types and reduces the quality of life. Overweight and obesity are the 
fifth leading risk for global deaths. 44% of the diabetes burden, 23% of the ischaemic heart 
disease burden and between 7 – 14% of certain cancers are attributable to overweight and 
obesity (4). In 2010, overweight and/or obesity was estimated to cause 3.4 million deaths 
worldwide (5). Additionally, obesity puts an enormous burden on patients, their families, and 
social health care systems. Therefore, it is important to explore underlying mechanisms that 
cause obesity and related chronic diseases. 
Obesity is linked to the development of insulin resistance, which is a major contributor 
to hyperglycemia and hyperlipidemia. These are all risk factors towards the development of 
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type 2 diabetes and cardiovascular diseases. Strikingly, insulin resistance increases the risk for 
cardiovascular diseases even in the absence of hyperglycemia (6).  
From 2011 – 2012, in the USA, the direct cardiovascular disease-related costs were 
estimated on 193.1 billion US dollars, which reflect e.g. hospital services, prescribed 
medication and home health care. In addition, indirect cardiovascular disease-related costs, 
such as loss of future productivity, were estimated to be about 123.5 billion US dollars (7). 
For diabetes, it has been estimated that the direct annual cost of diabetes to the world is more 
than 827 billion US dollar (8). Together, for cardiovascular disease and diabetes costs 
combined, this adds up to more than 1,143  billion US dollars in one year. In 2011, in the 
Netherlands, the total direct cardiovascular disease-related costs were 8.3 billion euro, which 
was 9.2% of the total Dutch healthcare costs (89.4 billion euro), while diabetes-related costs 
were estimated to be 1.7 billion euro (1.9%) (9). Although these numbers cannot only be 
subscribed to obesity-related cardiometabolic diseases, the expectation is that obesity and thus 
obesity-related morbidity will continue to increase in the coming years. Therefore, it will have 
major public health and socioeconomic consequences.  
Relevance of measurements for targeted prevention 
Recognition of symptoms at an early stage and early treatment of obesity and cardiometabolic 
diseases is important as it may prevent or delay the development of comorbidities. In addition, 
quality of life will be maintained or improved if weight and blood glucose concentrations can 
be well-controlled. However, obesity and cardiometabolic diseases are complex metabolic 
diseases whereby underlying mechanisms are yet not completely understood. Thus, 
understanding the etiology of obesity and insulin resistance is a key step in the prevention of 
cardiometabolic diseases. In this thesis, we focused on expanding fundamental knowledge 
about lipid metabolism in relation to early stages of insulin resistance. Although the findings 
may not lead to societal benefits at first glance, they generate improved insight into the 
pathophysiology of lipid metabolism in relation to whole-body and tissue-specific insulin 
resistance, which adds fuel for thought on future research initiatives.    
The various measurements described in this thesis, e.g. plasma lipidomics and adipose 
tissue transcriptomics, may be future markers to detect the presence of insulin resistance at an 
early stage. One key finding in this thesis was that distinct plasma lipid profiles were associated 
with either muscle insulin sensitivity or hepatic insulin resistance in overweight and obese 
individuals. As an example: we showed that muscle insulin resistance was associated with 
lower plasma concentrations of the lipid lysophosphatidylcholine. Future clinical and 
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mechanistic studies will have to investigate whether monitoring lipid profiles as a risk marker 
will prove to be clinically useful in the treatment or prevention of cardiometabolic diseases. 
Importantly, we also observed distinct plasma lipid profiles for men and women. Hepatic 
insulin resistance was higher in men compared to women. However, in women worse hepatic 
insulin resistance was associated with an increase in plasma TAG and diacylglycerol 
concentrations. This aspect of lipid metabolism in relation to sexes is currently very much 
underemphasized in research and underscores the importance for sex-specific research as this 
may improve targeted prevention for the individual sexes.   
In addition to fasting lipid metabolism measurements, it is a given that the majority of 
the population in the Western world spends a significant part of the day in the postprandial 
state. Increasing evidence suggests that not only fasting lipid, lipoprotein and glucose 
concentrations, but also a disturbed postprandial lipid or glucose metabolism are important 
risk markers for cardiometabolic diseases. Postprandial measurements are therefore of clinical 
importance when cardiometabolic disease risk is studied. In chapter 2, we extended existing 
knowledge on postprandial lipid metabolism. We showed that insulin resistance is associated 
with increased postprandial very-low-density-lipoprotein (VLDL) triacylglycerol extraction 
across the forearm muscle, despite a similar supply of triacylglycerol. In addition, different 
lipid composition patterns were observed in the skeletal muscle lipid pools in insulin 
resistance, which were mainly related to an increased saturation of the intramyocellular non-
esterified fatty acid pool. Ultimately, these events, e.g. elevated skeletal muscle VLDL-
triacylglycerol extraction and changes in intramuscular lipid composition, may give rise to 
increased muscle storage of detrimental bio-active lipid intermediates. They may affect insulin 
sensitivity in a negative way and contribute to cardiometabolic complications. 
Innovation and translation into practice 
The results described in this thesis have and will become available to the scientific community 
via publication of scientific reports in international peer-reviewed journals in the field of 
obesity and diabetes. Additionally, results have been presented at (inter)national conferences 
to scientists as well as physicians, healthcare professionals and dieticians, working in the fields 
of obesity, diabetes and metabolism.  
Changes in lifestyle are considered to play an important role in the etiology of obesity 
and cardiometabolic diseases. Manipulation of diet and physical activity are the first-choice 
treatment for these complications. Lifestyle interventions including combined diet and 
physical activity have been shown to be effective in the prevention of type 2 diabetes as they 
 196  | 
 
Addendum 
 
reduce diabetes incidence by 47 - 57% over a 3 - 6 year timeframe (10). In addition to lifestyle 
interventions, pharmacological modulation may also prevent or delay the onset of 
cardiometabolic complications (11). Healthcare professionals (e.g. dieticians, physiotherapists 
and physicians) play an important role in stimulating a healthy lifestyle among individuals 
who are at increased risk of developing obesity and cardiometabolic diseases. Although the 
results from this thesis do no provide direct guidelines for healthcare professionals, they 
provide better insight in metabolic parameters that can be targeted through lifestyle and 
pharmacological interventions.  
In chapter 5 and 6, we showed distinct metabolic profiles for muscle or liver insulin 
resistant conditions, based on the surrogate insulin sensitivity indexes MISI and HIRI. We 
estimated tissue-specific insulin resistance by using a 2 hours oral glucose tolerance test 
(OGTT), with glucose and insulin measurements at five time-points. Importantly, both 
indexes were developed and validated against the two-step gold standard hyperinsulinemic-
euglycemic clamp in combination with a glucose tracer (12). In the future, these indexes may 
provide a relatively easy method to classify and identify tissue-specific insulin resistant sub 
phenotypes as the OGTT is already widely used in the clinic to assess (gestational) diabetes.  
In this thesis we revealed distinct metabolic profiles under different tissue-specific insulin 
resistant conditions, and the  exact  mechanisms  behind  this  are  possibly  interesting for 
the food and pharmaceutical industry to guide development of more personalized targeted 
nutritional and lifestyle interventions. It should be noted that most associations presented here 
were based on cross‐sectional data and therefore cannot distinquish cause and consequence. 
But the DiOGenes project is a valuable cohort study for follow‐up measurements after diet-
induced weight loss and weight regain. Therefore future follow-up of the data after the weight 
loss intervention may elucidate the temporality of the associations reported or elucidate 
potential interesting mechanisms. Still,  more  mechanistic  studies  are  needed  to  find  
which  pathway(s)  need(s)  to  be  targeted  to maintain lipid homeostasis and insulin 
sensitivity.  
Notably, key findings of this thesis, i.e. distinct metabolic profiles for muscle or liver 
insulin resistant conditions, have already served as starting point for developing personalized 
dietary intervention strategies. Recently, a new research project was started in collaboration 
with the public-private partnership Top Institute Food and Nutrition (TIFN) to investigate 
optimal diets to maintain postprandial blood glucose homeostasis in tissue-specific insulin 
resistant subphenotypes. The ambition of this private-public partnership is to provide the 
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knowledge base that is needed for more targeted nutritional interventions in the prevention 
of cardiometabolic diseases and high-impact innovations in food and nutrition. The close 
collaboration between industry and academia leads to demand-driven research with societal 
and industrial relevance.  
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Zo, eindelijk is het moment daar dat ik het dankwoord mag gaan schrijven. Promoveren kun 
je zeker niet alleen doen en een goede samenwerking is onmisbaar. De afgelopen jaren hebben 
veel mensen mij hierbij geholpen en ik wil ze daar graag voor bedanken.   
Ellen, als promotor verdien jij zeker de allereerste plaats hier. Ik ben ontzettend blij dat 
je mij de kans hebt gegeven om in de wereld van het humane onderzoek te stappen. Ik zal 
mijn eerste werkdag nooit meer vergeten, waarbij ik binnen een kwartier al naast een 
proefpersoon aan het bed stond. Ik heb ontzettend veel geleerd van jou. Jouw 
wetenschappelijke inzicht en je omgang met PhD studenten zijn bewonderenswaardig. Je hebt 
een snelle kritische blik en jouw vragen tijdens onze werkbesprekingen zorgden voor nieuwe 
energie en motivatie bij mij. Als ik weer eens gefrusteerd binnen kwam, vaak omdat ik teveel 
antwoorden uit mijn data wilde halen, dan wist jij me toch altijd weer te kalmeren en mij te 
wijzen op de kracht van de humane data.  
Johan en Marleen, mijn copromotores, ben ik ook veel dank verschuldigd. Johan, bedankt 
voor al je inzichten en ondersteuning tijdens mijn promotietraject. Jouw fysiologische kennis 
en onuitputtelijke creatieve brein in het genereren van nieuwe ideeën waren heel inspirerend 
en zorgden ervoor dat ik steeds weer een stukje verder kwam. Marleen, jij werd pas in mijn 
laatste jaar officieel copromotor, maar je toegevoegde waarde was groot. Jouw zeer gedegen 
wetenschappelijke aanpak en jouw geduld om mij statistiek weer eens uit te leggen zorgden 
ervoor dat ik niet meer als een berg opkijk tegen data analyse. Ellen, Johan en Marleen, dank 
jullie wel voor een stimulerende omgeving, waarin mijn drang naar hoogwaardig onderzoek 
doen volledig werd gesteund.  
I would also like to thank all members of the thesis assessment committee, prof. M. 
Hesselink, prof. W. van Marken Lichtenbelt, prof. E. Feskens, dr. M. Brouwers and 
dr. L. Hodson for taking the time and effort to review my thesis and being present at the 
official PhD defence. 
Gijs, ook al was je niet direct onderdeel van mijn promotieteam, bedankt dat ik altijd met 
mijn vragen bij je terecht kon en voor de vele wetenschappelijke discussies. Daarnaast was het 
ook altijd gezellig met jou op verschillende congressen en in de auto naar Eindhoven als je me 
weer eens een lift gaf. Dankjewel. 
Wetenschap is een teamsport en onmogelijk zonder de input van de coauteurs. Zonder 
jullie hulp waren de artikelen in dit proefschrift niet zo uitgebreid geworden. Nicole V., ik wil 
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jou heel erg bedanken voor je hulp bij allerlei statistische analyses en ook jouw uitleg om het 
voor mij begrijpbaar te maken. Ook vond ik het gezellig om met jou een kamer te delen in 
Porto! Mirella, we had a tough time with our RNAseq analyses, but we managed! Thank you 
for everything and especially the Friday morning chocolate croissants. Michiel, jouw kennis 
van RNAseq analyses was van onschatbare waarde. Gabby, het was gezellig en leerzaam om 
met jou over allerlei organisatorische zaken te praten. And all the other members of the 
MUMC2020 project and other coauthors, I would also like to thank you for the pleasant 
cooperation and for the excellent contributions to improve the work that is presented in this 
thesis. Dankjulliewel. 
Zonder toegewijde proefpersonen had dit proefschrift nooit tot stand kunnen komen. 
Mijn oprechte dank gaat daarom uit naar alle mensen die hebben deelgenomen aan de 
onderzoeken in dit proefschrift; voor hun moeite en vooral voor het afstaan van bloed, vet- en 
spierweefsel. Dankjulliewel. 
Mijn paranimfen verdienen een extra woordje van dank. Rudi, ik begon als 
onderzoeksassistent op jouw onderzoek en direct voelde ik dat het een goede samenwerking 
zou worden. Samen deelden wij een kantoor, vele intensieve testdagen en wisten we jouw 
hectische eerste studie efficiënt tot een goed einde te brengen. Ik heb je leren kennen als de 
rustige ‘Belg’ met droge humor die overdag ontzettend hard kan werken, maar ’s nachts ook 
heel hard kan feesten, zoals op het congres in Barcelona en alle andere feestjes. Bedankt voor 
alle leuke tijden die we samen hebben gehad. Kelly, we werden kantoorgenoten in een 
belangrijke fase van mijn promotietraject: het laatste jaar. Jouw vrolijke positieve instelling 
zorgden voor een fijne werksfeer: we werkten wanneer er gewerkt moest worden, maar er was 
meer dan genoeg tijd om plannen te maken voor congressen, feestjes en allerlei andere 
activiteiten. Ook bedankt voor het luisteren naar mij als ik weer eens teveel stress voelde. 
Succes met jouw promotieonderzoek! Rudi en Kelly, ik ben ontzettend blij dat jullie mijn 
paranimfen willen zijn en ik zie er naar uit dat jullie aan mijn zijde staan! 
Nadia, jouw deur stond altijd open voor mij en daar maakte ik gretig gebruik van. Naast 
de vele wetenschappelijke discussies die we hebben gehad, waarbij ik jouw rustige 
meedenkende houding heel erg heb gewaardeerd, was er ook genoeg tijd voor ontspannende 
koffie-dates met uiteenlopende onderwerpen. Onze gezamelijke reis naar Oslo was een 
hoogtepunt (onder andere de skischans). Dankjewel en ik hoop dat we nog lang vriendinnen 
zullen blijven. 
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Dorien, Emanuel en Cyril: wat een leuke jaren hebben we gehad tijdens onze promotie! 
Dorien, met jouw gigantische humane studie en jouw vele verhalen vlogen de dagen op het 
werk voorbij. Toffe congressen (sorry voor alle slapeloze nachten…), feestjes en allerlei andere 
activiteiten zijn door jou gelukkig ook altijd uitgebreid op beeld vastgelegd, zodat ik ze niet 
zal vergeten. Ik hoop dat we nog lang vriendinnen zullen blijven. Manu, brainstormen met 
jou was altijd heel fijn. Nadat je van kantoor verhuisd was, vond ik het fijn dat we dit bleven 
doen tijdens onze wandelingen en ‘koffie’tjes’, naast alle andere onderwerpen die we dan ook 
bespraken. Cyril, onze korte tijd als kantoorgenoten was zeer plezierig door jouw vriendelijke 
persoonlijkheid en grote kennis. En wat betreft de open ramen: die zorgden voor verfrissende 
ideeën ;). Bedankt voor jullie altijd positieve aanwezigheid! 
Mattea, Qing, Max en Inez. You are great collegues and I enjoyed our regular lunches at 
work a lot! Mattea, we shared an office for almost two years and we always had fun if we 
managed to be there at the same time, haha. Qing, it was really nice to have you around and 
I learned a lot about China and its culture. Max, je bent een heel gezellige collega met wie ik 
het over van alles kan hebben. Inez, jouw stipte koffietijd om 9u ga ik zeker missen en 
dankjewel dat je mijn vooroordelen over korfbalmeisjes voor altijd positief hebt veranderd ;). 
Thank you all for being there and good luck with your PhDs! 
De overige (ex)collega’s van de onderzoeksgroep: Jasper, Laura, Kenneth V., Nicole H., 
Yvonne, Ruth, Rens, Roel, Adriyan, Manuel, Suzanne, Sini, Elaine, Kenneth P., bedankt 
voor alle wetenschappelijke discussies en de leuke tijden die we samen hebben gehad tijdens 
onze werkbesprekingen, congressen en feesten. Jullie zijn een toffe groep collega’s waar het 
goed mee vertoeven was, ook buiten het werk om. Laura, ik had veel bewondering voor jouw 
omgang met proefpersonen en je open persoonlijkheid. Nicole H. en Yvonne, jullie zijn top 
analisten! Dankjulliewel voor de goede begeleiding op het lab en de vele gezellige uren die we 
samen op ons kantoor hebben doorgebracht.  
De afgelopen jaren heb ik ook vele uren in de trein doorgebracht op het traject 
Eindhoven-Maastricht en gelukkig waren daar de ‘Treinhomies’ op ons vaste plekje voorin de 
trein. Sophie, onze BVO’tjes na (en meegenomen van) de vrijdagmiddagborrel smaakten altijd 
goed. Nik, jouw aanwezigheid maakte de dagelijkse treinreis meer dan goed met je 
onuitputtelijke verhalen en filmkennis. Boris, meerdere malen was onze treinreis één grote 
pubquiz en gaf je mij met al je (vreemde) gedachtenpatronen een grote glimlach :). Marije, 
we hebben het langst samen dit traject afgelegd en samen zaten we in de laatste loodjes van 
onze promotietraject. De uren in de trein, en niet te vergeten die op de wielrenfiets naar huis, 
 202  | 
 
Addendum 
 
waren altijd een lichtpuntje en een mooi moment om de dagelijkse beslommeringen door te 
nemen, mede door jouw opgewekte instelling. Binnenkort ga ook jij promoveren met een heel 
mooi proefschrift. Allemaal heel erg bedankt voor jullie gezelschap in deze vele reisuren! 
Desiree, Cleo en Claudia, dankjulliewel voor een warm en verwelkomend secretariaat. 
Jullie prettige ondersteuning bij allerlei organisatorische zaken en jullie open deur zijn 
onmisbaar voor de afdeling!  
Al mijn HB/BW collega’s: bedankt voor de leuke momenten gedurende de afgelopen 5,5 
jaar! Er waren veel activiteiten zoals meerdere keren in het jaar weekendjes weg in de 
Ardennen, carnaval, feestjes, lunches, de gezellige kerstdiners en de feestjes die daarop 
volgden. Ik zou iedereen hier wel persoonlijk willen bedanken, maar het zijn er gewoon te veel 
en ik wil niemand vergeten. Jullie hebben allemaal bijgedragen aan mijn fantastische tijd in 
Maastricht. Toch een speciaal woord van dank voor Jos die me altijd stipt op vrijdagmiddag 
om 16u aan de borrel herinnerde en zijn grote inzet om alle HB/BW mensen bijeen te 
brengen. Ook alle ‘M3 Cycling’ collega’s bedankt voor de vele prachtige fietstochten door 
Zuid-Limburg, dit waren mooie hoogtepunten afgelopen jaar! 
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